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CAL Clinical attachment loss
CRP C-reactive protein
CTLP Chymotrypsin-like proteinase, dentilisin




ELISA Enzyme-linked immunosorbent assay
E-selectin Endothelial leukocyte adhesion molecule
GCF Gingival crevicular fluid
HMT Host modulation therapy
IL Interleukin
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NF-kB Nuclear factor kappa B
OPG Osteoprotegrin
PAMP Pathogen-associated molecular pattern
PGE Prostaglandin E
PBI Papillae bleeding index 
PPD/PD Probing/Pocket depth 
PRR Pattern recognition receptor
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PD Pocket depth
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Active matrix metalloproteinase (aMMP-8), collagenase-2, is a key mediator in the 
destruction of tissues seen in periodontitis and peri-implantitis. It can be detected in oral 
fluid samples, including gingival crevicular fluid (GCF), saliva, mouth rinse and peri-im-
plant sulcular fluid (PISF). Active MMP-8, which is mainly expressed by neutrophils, can 
degrade almost all extracellular matrix and basement membrane components; it is causes 
particularly high levels of degradation in type I collagen, which is present in periodontal 
ligaments.
In the first part of this thesis, we demonstrated that during an experimental gingivitis study 
aMMP-8 was not detectable in saliva. Therefore, this study confirms the evidence; aMMP-8 
is detected in periodontitis. Simultaneously, the lateral-flow chairside aMMP-8 immuno-
tests, PerioSafe and ImplantSafe with the Oralyzer reader, which are based on Professor 
Timo Sorsa’s research, were introduced and validated to analyse the levels of aMMP-8 in 
mouth rinse or PISF. Thus, the last parts of the thesis evaluate the accuracy and reliability of 
these developed tools: PerioSafe and ImplantSafe/Oralyzer, and whether they could provide 
an easy-to-use and quick way of identifying periodontitis and peri-implantitis.
Our results indicated that the tools were successful in their detection. They were also very 
accurate in terms of both sensitivity and specificity with clinical periodontal parameters, 
such as bleeding on probing (BOP) and plaque index (PI). In addition, study V has inves-
tigated the effectiveness of sub-antimicrobial doses of doxycycline (SDD) treatment when 
combined with non-surgical periodontal therapy, and their effect on potential GCF bio-
markers in periodontal tissue destruction over a period of twelve months. The analysed 
biomarkers were MMP-8, -9, -13, myeloperoxidase (MPO), osteoprotegerin (OPG), and 
tartrate-resistant acid phosphatase 5 (TRAP-5), which were determined by various immu-
nofluorometric analyses (IFMA) and enzyme-linked immunosorbent assays (ELISAs). The 
results demonstrated reduced GCF levels in two MMPs that most commonly associated 
with periodontitis; MMP-8 and -9, and MPO, which potentially causes oxidative activation 
in them. However, MMP-13 and TRAP-5 could be detected in the relevant GCF samples, 
whereas the OPG levels also decreased significantly as a result of adjunctive SDD therapy. 
This thesis showed the reliability of these tools, PerioSafe and ImplantSafe/Oralyzer, for 
the successful detection, prediction and monitoring of the progress of periodontitis and 
peri-implantitis, and their response to treatment. Additionally, we delved further in to the 




Periodontitis and peri-implantitis are common across the globe. They are inflammatory 
disorders that affect the teeth and dental implants. They are caused by infection, and both 
actively degrade and destroy periodontal, peri-implant soft and hard tissues. Periodontal 
and peri-implant tissues are mainly made up of type I collagen. The proteolytic enzyme, 
which is known to cause the majority of active periodontal/peri-implant soft and hard 
tissue degeneration (APD), is MMP-8, also known as neutrophil collagenase or collage-
nase-2. MMP-8 belongs to the MMP family. Ca2+ and Zn2+ -dependent endopeptidases are 
genetically different MMPs but they have a similar structure. They are capable of degrading 
most extracellular matrix and basement membrane protein components in both the physi-
ologic repair and pathologic destruction of tissues, such as healing wounds, tissue remodel-
ing and embryonic development (Kinane et al. 2000, Nagase et al. 2006).
In the MMP family, MMP-8 is part of the interstitial collagenase subgroup. Whereas 
α2-macroglobulin and TIMPs regulate MMP activity. When levels of MMPs and TIMPs in 
tissues are imbalanced, this can lead to irreversible periodontal and peri-implant destruc-
tive pathology involving soft and hard tissue degeneration. Periodontopathogenic bacteria 
and their virulence factors, in combination with host-derived proinflammatory mediators, 
trigger degranulation. Such degranulation leads to MMP-8 being released from neutrophils 
(Sorsa et al. 2006, 2016, Bernasconi et al. 2015). Links have recently been made between 
elevated MMP-8 levels in oral fluids, particularly the active form of MMP-8 (aMMP-8), 
and periodontal and peri-implant inflammation disorders (Sorsa et al. 1988, Cox et al. 
2006, Al-Majid et al. 2018). Levels of active MMP-8 are directly associated with progres-
sive periodontal and peri-implant disease activity, and they can therefore be used to pre-
dict the development and progression of these diseases. Positive correlations have been 
found between elevated levels of aMMP-8 in oral fluids, such as gingival crevicular fluid 
(GCF), mouth rinse, saliva and peri-implant sulcular fluid (PISF), and clinical periodontal 
parameters, such as bleeding on probing (BOP), probing pocket depth (PPD, which is in 
this work abbreviated as PD) and clinical attachment loss (CAL). When periodontal and 
peri-implant treatments are used successfully, aMMP-8 levels can be decreased (Hernandez 
et al. 2010, Thierbach et al. 2016, Mauramo et al. 2018). 
Periodontitis can be treated in a simple and inexpensive way if it is diagnosed at an early 
development stage. This can be challenging since the disease tends to be asymptomatic. 
Therefore, highly trained professionals and specific equipment are needed for a diagnosis 
purposes. and these are not always available in areas that are poor in resources (Mohd-Dom 
et al. 2014, 2016). Recently, the aMMP-8 PerioSafe and ImplantSafe tests were introduced; 
they utilise an Oralyzer reader, which provides quantitative results, and they are used to 
diagnose periodontitis and peri-implantitis. The tests, which are similar to pregnancy tests, 
are easy to use and can be carried out at the point-of-care. Studies have already confirmed 
Introduction
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the accuracy of their diagnoses. The tests measure aMMP-8 levels in oral fluid with a lateral 
flow immunoassay, and the results can be used to assess the inflammatory burden of the 
periodontium (Sorsa et al. 2016, Heikkinen et al. 2016, Raisanen et al. 2019). 
Liquid chromatography mass spectrometry (LC-MS) -based proteomic approaches have 
proven valuable for assessing proteins in the saliva of both healthy and diseased patients. 
Although over 5,000 proteins have been identified in saliva, it is difficult to further charac-
terise them as there are not enough antibodies available with high specificity for all of these 
proteins. Furthermore, none of these approaches have been applied in the clinical diagnosis 
of periodontitis. For this reason, antibody-based immunoassays, which employ antibodies 
that target a specific protein, are the main method for the quantification of proteins (Grassi 
et al. 2016, Bostanci et al. 2017).
In inflammatory diseases, such as periodontitis, it is important to be able to modulate the 
inflammatory responses and manage the outcomes. Although some inflammatory mech-
anisms aim to protect, they can actually result in self-damage if the inflammation is not 
resolved sufficiently. The sub-antimicrobial doses of doxycycline (SDD) therapy can be used 
effectively to manage periodontitis when combined with non-surgical therapy because it 
can regulate the host response (Golub et al. 2020, Sorsa et al. 2020). Numerous studies have 
demonstrated that SDD can affect the production of MMP-8 and collagen metabolism, thus 
preventing bone loss and the progression of periodontitis. It is believed that MMPs play a 
role in the periodontal tissue destruction during the inflammatory process, in which cyto-
kine and chemokine networks, and the host’s immune response are heavily involved (Golub 
et al. 2020, Sorsa et al. 2020).
Introduction
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2.  LITERATURE REVIEW 
Human matrix metalloproteinases (MMPs) are a family of enzymes that are structurally, 
but not genetically, similar. The group consists of 23 calcium-dependent and zinc-depen-
dent endopeptidases (Nagase et al. 2006, Jackson et al. 2010, Butler et al. 2013, Checchi et 
al. 2020). MMPs play a crucial role in tissue remodelling, development and homeostasis 
and they regulate a variety of functions such as cell differentiation, migration and apoptosis 
(Nyberg et al. 2006, Hannas et al. 2007). In addition, they are capable of destroying most 
extracellular matrix (ECM) and basement membrane (BM) protein components. Con-
nections have been made between a large number of inflammatory disorders and MMPs 
(Nagase et al. 2006, Van Lint et al. 2006, Morais et al. 2017). There is plenty of evidence 
to support the fact that MMP upregulation and downregulation occurs as a response to 
inflammatory mediators, such as cytokines and chemokines (Franco et al. 2017, Roomi et 
al. 2017). Activated MMPs can also activate other MMPs (Vu and Werb 2000, Page-Mc-
Caw et al. 2007). In most cases, MMPs are synthesised and secreted as proenzymes. Latent, 
proMMPs can be activated in three ways: (1) intracellularly, (2) at the cell surface by mem-
brane-type (MT‐) MMPs, and (3) extracellularly by other proteases (Visse and Nagase 
2003, Holopainen et al. 2003). Other MMP activators include serine proteinase, such as 
plasmin and trypsin (particularly human trypsin-2) (Sorsa et al. 1997, Visse and Nagase 
2003, Bjorklund and Koivunen, 2005). The initial activation of serine proteinase in the 
proMMP activation cascade is thought to occur with human trypsin‐2 (Sorsa et al. 1997). 
Human trypsin‐2 is also responsible for the direct degrading of native interstitial collagen 
types I and II (Stenman et al. 2005).
Cysteine proteinases released from gingival fibroblasts and proforms of serine proteinases 
can result in proMMP activation (Cox et al. 2006). ProMMPs can be activated by reactive 
oxygen species (ROS) as well as bacterial and candidal proteinases (Saari et al. 1990, Sorsa 
et al. 1992). The typical uniformity of different activation pathways is that the molecular 
weight of proMMPs changes when the N-terminal propeptide is cleaved and removed, 
and the active forms are usually 10 – 20 kDa less than the proforms (Nagase et al. 2006, 
Page-McCaw et al. 2007). When physiological conditions are normal, there is a balance 
between active and inactive MMPs. If this balance is disrupted, excess tissue destruction 
and pathological conditions, such as periodontitis, can occur (Mantyla et al. 2006, Sorsa et 
al. 2006, Visser and Ellen 2011).
MMPs are classified into six protease groups based on substrate specificity, domain struc-
ture and cellular localization: collagenases (MMP-1, MMP-8 and MMP-13), gelatinases 
(MMP-2 and MMP-9), stromelysins (MMP-3, MMP-10), matrilysins (MMP-7, MMP-26 
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and MMP-11), membrane-type (MT-) MMPs (MMP-14, MMP-15, MMP-16, MMP-17 
MMP-24 and MMP-25) and others MMPs (Stocker et al. 1995, Nagase et al. 2006).
MMPs have a common domain structure, which consists of a pro-domain, catalytic domain 
and hemopexin domain. There are 80 amino acids in the pro-domain, around 170 in the 
catalytic domain and about 200 in the hemopexin domain. The pro-domain has a highly 
conserved cysteine residues, which are able to bind to the zinc ion in the catalytic domain 
(Nagase et al. 2006). Activation occurs when the pro domain is removed, and the catalytic 
site is revealed and prepared for enzymatic activity. A linker peptide (the hinge region) acts 
as a contact point between the hemopexin domain and the C-terminal domain (Nagase et 
al. 2006, Page-McCaw et al. 2007).
There are three main levels of MMPs regulation; gene expression, proenzyme activation 
and endogenous inhibition (Overall et al. 2002, Sorsa et al. 2016). MMPs can be inhibited 
by specific tissue inhibitors of metalloproteinase (TIMP-1, -2, -3, and -4), serine protein-
ase inhibitors, and non-specific endogenous inhibitors, such as α2-macroglobulin (Herman 
et al. 2001, Yabluchanski et al. 2013). In addition, low-dose-doxycycline/subantimicrobi-
al-doses of doxycycline (L/SDD) therapy can inhibit MMPs (Golub et al. 1995, 2020).
MMP-8 (neutrophil collagenase) is synthesised in the bone marrow during the myelocyte 
stage of neutrophil development. It is stored in specific granules (Hanemaaijer et al. 1997). 
There are also other mesenchymal cell sources that express and secrete MMP-8 in smaller 
quantities that are less glycosylated than the polymorphonuclear leukocytes (PMNs) (Sorsa 
et al. 1997, Hanemaaijer et al. 1997). Non-PMN lineage cells include epithelial cells, fibro-
blasts, osteoblasts, odontoblasts and endothelial cells (Tervahartiala et al. 2000, Palosaari et 
al. 2000, Wahlgren et al. 2001, Owen et al. 2004).
Periodontopathogenic bacteria as well as their virulence factors, such as microbial-de-
rived proteases, can cause stimulation of neutrophil degranulation during phagocytosis. 
The microbial-derived proteases generally include gingipains, trypsin-like cysteine pro-
teinases of Porphyromonas gingivalis (P. gingivalis), and dentilisin (Td-CTLP), a chymo-
trypsin-like proteinase of Treponema denticola (T. denticola) (Imamura et al. 2003, Gursoy 
et al. 2018). Neutrophil degranulation is also triggered by prostaglandins and cytokines, 
which include host-derived inflammatory mediators, such as the tumour necrosis factor 
(TNF-α) and interlukine (IL-1β) (Ryan et al. 1996, Sorsa et al. 1992, 2004). Subsequently, 
neutrophil degranulation leads to the release of latent MMP-8 from specific granules and 
MPO from the primary granule (Saari et al. 1990, Tervahartiala et al. 2000, Leppilahti 
et al. 2014). The conversion of the potent oxidant, hypochlorous acid (HOCl), is cata-
lysed by myeloperoxidase (MPO). This not only involves antimicrobial activity, but it also 
modifies the balance between proteases/anti-proteases by playing a significant role in 
Literature review
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how connective tissue catabolism and degradation are regulated (Wang et al. 2007, Khan 
et al. 2018). Depending on the oxidant/enzyme molar ratio, HOCl can quickly activate 
proMMP-8 and proMMP-9 (Weiss et al. 1985, Peppin et al. 1986, Saari et al. 1990, Sorsa 
et al. 2006). MPO in the neutrophils’ primary granules can participate in MMP-8 acti-
vation, which supports the oxidative role of MPO in the activation of latent MMP-8 
and MMP-9. Similarly, the inactivation of TIMP-1 is based on evidence concerning 
progressive chronic periodontitis in humans (Hernandez et. al 2006, Marcaccini et al. 
2010). Furthermore, MMP-8 and MPO show a highly specific site-diagnosis of chronic 
periodontitis. All in all, these findings indicate that MPO enhances MMP-8 activation 
during the progression of periodontal disease (Leppilahti et al. 2014). The known ECM 
substrates of MMP-8 are collagens types I, III, VII, X, gelatine, fibrinogen, bradykinin and 
angiotensin, as well as pro-inflammatory and anti-inflammatory cytokines/mediators. In 
addition to this, MMP-8 can inactivate the α2-macroglobulin and α1-proteinase inhibitors 
(Hasty et al. 1987, Diekmann et al. 1994, Hiller et al. 2000, Sternlicht and Werb 2001).
Collagen type I is the main substrate of MMP-8. The ECM protein in several different 
tissue types, such as periodontium, is mainly structured by this collagen. MMP-8 remodels 
and degrades the vascular basement membrane and ECM, allowing leukocytes to trans-
migrate into the inflammatory site. Furthermore, MMP-8 also degrades several non-ECM 
substrates, such as chemokines, and protease inhibitors (Van Lint and Libert 2006). Neu-
trophils play an important role in the innate immunity system and removing pathogens. 
The movement and chemotaxis of neutrophils rely on MMP-8 being released (Nauseef 
2007, Tester et al. 2007). However, excessive damage and degradation of tissues can lead 
to destructive inflammation, which in turn is caused by neutrophil degranulation, and the 
release and activation of MMP-8. Therefore, MMP-8 contributes significantly in a number 
of inflammatory disorders that lead to the destruction of tissue, such as periodontitis (Herr 
et al. 2007, Sorsa et al. 2016, Morais et al. 2018). MMP-8 is also associated with the cancer 
progression and the healing of wounds (Dejonckheere et al. 2011, Rohani and Parks 2015). 
MMP-8 in oral fluid can be found in different molecular forms, wherein the complex form 
is >110 kDa, the latent and active neutrophilic form is 85-65 kDa, the latent and active mes-
enchymal-type collagenase form is 65-45 kDa and fragments are 30-20 kDa (Hanemaaijer 
et al. 1997, Geijersstam et al. 2005, Gursoy et al. 2018).
The MMP-8 gene is situated in the cluster of MMP genes in 11q22.3 (Hasty et al. 1990, 
Pendás et al. 1996). The gene’s activity is regulated by three single-nucleotide polymor-
phisms (SNPs) in the promoter region of MMP-8, −799C/T (rs11225395), −381A/G 
(rs1320632), and +17C/G (rs2155052) (Wang et al. 2004). According to Heikkinen et al. 
(2016), MMP-3 and vitamin D receptor genetic polymorphisms were reported to be asso-
ciated with initial periodontitis in Finnish adolescents. In contrast, there was no associa-
tion between SNPs and aMMP-8. However, further research needs to be carried out into 
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how these polymorphisms affect MMP-8 tissue concentrations (Aquilant et al. 2007, Prad-
han-Palikhe et al. 2012). 
The expression of MMP-13 (collagenase-3) is very restricted but it has a broad substrate 
specificity. It is an efficient catalyst enzyme (Knauper et al. 1996, Ala-aho et al. 2005, 
Checchi et al. 2020). MMP-13 was first found to be expressed in breast carcinomas (Freije 
et al. 1994), and later, it has been identified in human periodontitis (Uitto et al. 1998). This 
suggests that it facilitates the conversion of pocket epithelium into periodontal connective 
tissue through the lamina propria stromal cells of the gingival sulcus, such as macrophage 
and fibroblasts (Uitto et al. 1998, Tervahartiala et al. 2000, Kiili et al. 2002). MMP-13 is a 
very efficient degrader of collagen type II – it is ten times more efficient than other colla-
genases (Knauper et al. 1996). MMP-13 is secreted as a 60 kDa glycoprotein, which is con-
verted to 48 kDa during proteolytic activation (Moilanen et al. 2003, Virtanen et al. 2017). 
GCF samples were taken from periodontitis patients before they underwent treatment, and 
immunoblotting assays for MMP-13 revealed complex, proenzyme and activated enzyme 
forms. Samples that were taken after scaling and root planing (SRP) contained significantly 
less band absorbance (Golub et al. 1997, Kiili et al. 2002, Ilgenli et al. 2006). According to a 
study carried out by Ejeil et al. (2003), which investigated the possible correlation between 
the presence of enzymes, such as MMP-1, -2, -9, and -13, and collagen loss, GCF from 
patients with periodontitis contained proenzyme, active and fragmented forms of these 
enzymes. When they were present in human gingival explants, collagen fibres decreased. 
The conclusion made by the authors was that there was a link between these metallopro-
teinases and periodontitis-related ECM degradation. 
It has been suggested that MMP-9 (gelatinase-B) plays a role in the destruction of periodon-
tal tissue. Patients with periodontitis have been found to have elevated levels in their GCF, 
but these declined with conventional periodontal treatment (Makela et al. 1994, Ingman et 
al. 1996, Westerlund et al. 1996, Beklen et al. 2006). The degradation of a number of pro-
teins is also attributed to gelatinases: collagen types IV, V, VII, X and XI; elastin; and the 
components of basement membrane (Owen and Campbell 1999, Beklen et al. 2006). 
MMP-9 is most effective in degrading aggrecan, fibronectin, fibrillin and collagen types I, 
II, III, V, VI and X (Konttinen et al. 1998, Kahari and Saarialho-Kere 1999). In periodon-
titis, neutrophils are the principle source of MMP-9. Macrophages also produce MMP-9 
but to a lesser extent (Westerlund et al. 1996, Pirila et al. 2001). MMP-9 appears to be the 
principle gelatinase present in the gingival tissue, saliva, dental plaque and GCF of chronic 
periodontitis patients (Sorsa et al. 1995, Golub et al. 1995, Vandooren et al. 2013). 
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MPO is a lysosomal enzyme and can be considered to be a biomarker of inflammation 
and oxidative stress. It is mainly produced by neutrophils (PMNs) (Khan et al. 2018) and 
monocytes (Podrez et al. 2000). Its gene is located on chromosome 17 (Khan et al. 2018) 
and when active, its molecular weight is 150 kDa. The primary granules of PMNs store 
MPO (Cao et al. 1989, Borregaard et al. 2007). MPO is released into extracellular fluid 
through inflammatory mediators and oxidative stress. It has an antibacterial effect due to 
the secretion of H2O2 (Khan et al. 2018). MPO plays an essential role in oxidatively acti-
vating proMMP-8 and proMMP-9, and deactivating TIMP-1 (Saari et al. 1990). In addi-
tion, increased levels of MPO in oral fluid were detected in patients with periodontitis and 
peri-implantitis (Liskmann et al. 2004, Gursoy et al. 2013, Nizam et al. 2014). The oxidative 
effect of MPO is described in further detail in Section 2.1.2.
Neutrophil elastase is a serine proteinase and it is secreted by neutrophils’ azurophilic gran-
ules during phagocytosis stimulation and cell lysis. In the same way as other serine pro-
teinases, elastase has broad substrate specificity and it can degrade a range of tissue mol-
ecules, such as elastin, fibronectin, collagens, proteoglycan and laminins. It is thought to 
possibly have some direct anti-microbial characteristics. Increased levels of PMN elastase 
in different oral fluids, such as GCF and saliva, have been associated with periodontitis and 
peri-implantitis (Ingman et al. 1996, Nizam et al. 2014, Bujanda et al. 2019).
Tartrate-resistant acid phosphatase is a purple acid phosphatase that contains iron. Its 
expression is via osteoclasts and other monocyte–derived macrophage cells (Halleen et al. 
2003). When bone resorption occurs, TRAP-5 (or only TRAP) is secreted from osteoclasts 
and is indicative of the bone resorption rate. Research is currently being conducted into 
TRAP as a blood-borne biochemical marker for bone resorption and osteoclast activity. A 
correlation has been observed between TRAP serum concentrations and bone resorption 
rates. The administration of osteoprotegerin (OPG) reduces the amount of TRAP serum 
and osteoclastic bone resorption, which is a characterising feature of periodontitis progres-
sion (Halleen et al. 2003, Kirstein et al. 2006, Hienze et al. 2015). 
Osteoprotegerin is secreted by osteoblasts and several other types of cells. Many of the 
factors that regulate osteoblasts’ expression of receptor activator of nuclear factor kap-
pa-Β ligand (RANKL) also regulate the expression of OPG. Previous studies have not 
always been in agreement but generally it is accepted that if the up-regulation of RANKL 
expression occurs, OPG expression is down-regulated, or at least it is induced less than 
RANKL. Therefore, changes in the RANKL/OPG ratio favour osteoclastogenesis (Bostanci 
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et al. 2007, Hienze et al. 2015). The activity and numbers of osteoclasts may increase if the 
RANKL/OPG ratio changes due to either an increase in osteoclasts or a reduction in the 
RANKL/OPG ratio, or if both change in a way that alters the ratio to favour RANKL (Bos-
tanci et al. 2007, Hienze et al. 2015).
RANKL is a homotrimeric protein. It can be secreted by activated T-cells and is usually 
bound to the membranes of osteoblastic and activated T-cells. Alternative splicing or pro-
teolytic cleavage lead to the membrane form of the secreted protein (Crotti et al. 2003, Jin et 
al. 2007, Silva et al. 2015). 
Receptor activator of nuclear factor kappa-B (RANK) is a homotrimeric transmembrane 
protein belonging to the TNF receptor superfamily. In dendritic cells and mature osteo-
clasts, and at a protein level, its expression is lower than that of RANKL. It is expressed in 
mammary glands and certain types of cancer cells, such as prostate and breast cancer. If 
the concentrations of OPG are relatively high compared to the expression of RANKL, OPG 
binds with RANKL and prevents it from binding with RANK. This leads to a decreased 
number of osteoclasts being formed and apoptosis of existing osteoclasts (Mogi et al. 2004, 
Hienze et al. 2015).
TIMPs exert extracellular control over interstitial collagenases and other MMPs. Several 
different cells express TIMPs, particularly TIMP-1, such as monocytes/macrophages, host 
fibroblasts, osteoblasts, keratinocytes and endothelial cells (Meikle et al. 1994, Rayan and 
Golub 2000). TIMPs have also been observed in GCF. TIMPs play a role in regulating ECM 
metabolism, but their principal function is seen to be the inhibition of MMPs (Kahari 
et al. 1999, Folgures et al. 2004). The balance between MMPs and TIMPs is essential in 
controlling ECM degradation (Nagase et al. 2006). There are four members of the TIMP 
family: TIMPs 1–4. They present distinct expression profiles and biochemical characteris-
tics (Folgures et al. 2004). TIMP-1 is a 28 kDa glycoprotein, which has the ability to inhibit 
fast all MMPs, particularly MMP-1 (Nomura et al. 1993, Kubota et al. 1996). In GCF, higher 
TIMP-1 levels have been observed in periodontitis sites compared to healthy sites (Hae-
rian et al. 1995, Choi et al. 2004). Furthermore, the salivary TIMP-1 levels are significantly 
decreased following periodontal treatment (Hayakawa et al. 1994, Gursoy et al. 2010).
Periodontitis is widespread; 10-15% of adults across the world suffer from it (Petersen and 
Ogawa 2012). The percentage is much higher in the United States, where 46% of adults have 
periodontitis. Among these individuals, 8.9% suffer from severe periodontitis, which can 
severely affect their quality of life because it can lead to teeth loss and mastication difficul-
ties. (Eke et al. 2015).
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A number of clinical indices and measurements are applied in the diagnosis of periodontal 
diseases. These include BOP, PD, radiographs and CAL level assessments. Records are also 
made on the amount of plaque and any relevant medical and hereditary factors, such as cer-
tain systemic diseases. The symptoms of periodontitis include halitosis, bleeding, swelling 
and redness of the gingiva, gingival recession, or instability of teeth. A periodontal probe 
is used to measure the depth of periodontal pockets and to assist with a clinical diagnosis 
of periodontitis. If the pocket depth is 4 mm or more, the diagnosis is termed pathological. 
Radiographs are used to assess how much alveolar bone has been lost around the teeth, 
as this is a sign tissue destruction caused by episodes of periodontitis. There are often no 
symptoms until the teeth loosen, and the worst outcome is the loss of the affected teeth. The 
risk of this occurring is significantly greater if the periodontal pockets are 7 mm deep or 
more (Khan et al. 2015).
One definition for diagnosis is to use signs and symptoms to identify a disease, while clas-
sification is defined as the process of dividing into groups. A clinician’s diagnosis can be 
considered as an initial ‘best assumption’ concerning a patient’s state of health. The first 
periodontal classification system was introduced in 1989. The system had some significant 
issues; there was no clear definition between the various diagnostic categories or a standard 
foundation for classification (van der Velden 2017). In an attempt to overcome these issues, 
the International Workshop for a Classification of Periodontal Diseases and Conditions 
introduced a replacement classification system ten years later (Armitage 1999). The 1999 
classification system focused on the periodontitis progression rate. A case on periodontitis 
was classified as chronic if the alveolar bone loss had progressed slowly, and as aggressive if 
bone loss had progressed rapidly. 
Although this system was utilised across the world for the next 18 years, clinicians and 
researchers still experienced problems with its application. As the classification system had 
not really introduced any conceptual changes, it was still difficult to differentiate between 
chronic and aggressive periodontitis. This meant that data produced by different research 
centres could not be combined. The 2017 World Workshop proposed a new classification 
system for periodontal diseases. The European Federation of Periodontology (EFP) and 
the American Academy of Periodontology (AAP) participated in this workshop with the 
aim of developing a simpler system for general practitioners and periodontists. This system 
still did not differentiate between chronic and aggressive periodontitis as there was lack of 
evidence concerning their differences. However, the system categorised classical localised 
juvenile (aggressive) periodontitis as an individual phenotype. The classification system, 
which was introduced in 2017, specified the clinical attachment loss (CAL) as a factor for 
characterising the type on periodontitis, periodontitis, necrotising periodontitis or a man-
ifestation of systemic disease. The system also specified the progression rate of periodontal 
disease, which are stage I – IV (severity and extent of periodontal tissue destruction) and 
grade A – C (future risk of progression) (Papapanou et al. 2018, Tonetti et al. 2018). 
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The 2017 system also included grading parameters that could be used to evaluate the prob-
ability of periodontitis progression. However, the reliability of the parameters was not high 
enough to indicate when the active phase of periodontitis would occur, even when diabe-
tes- and smoking-related risk factors are considered (Leite et al. 2018, Nascimento et al. 
2018). Therefore, Tonetti et al. (2018) pointed out that there was still a need for more robust 
biomarkers to be introduced, which would allow clinicians to identify whether or not a 
case of periodontitis is in its active phase (continuing periodontal breakdown). This would 
also allow clinicians to monitor the progress of the disease and make decisions concerning 
appropriate treatment methods. 
There has been extensive research into the possibility of using oral fluids, such as GCF, 
saliva and mouth rinse, to find biomarkers that could be used to diagnose periodontitis. 
In recent decades, there have been several researchers searching for suitable biomarkers 
that can detect, predict and reflect the pathophysiology of periodontal and peri-implant 
diseases. However, a biomarker that has received a lot of research attention is MMP-8. 
A number of studies (Lee et al. 1995, Romanelli et al. 1999, Kiili et al. 2002, Sorsa et al. 
2006, Al-Majid et al. 2018, Sorsa et al. 2020) have reported that elevated levels of active 
MMP-8 are a precursor of periodontal attachment loss and can provide insight into making 
a distinction between gingivitis and periodontitis. The same is not true for latent or total 
MMP-8. 
The use of point-of-care (PoC)/chair-side tests, which are based on aMMP-8 measure-
ments, is demanding. Recently, simple, yet sophisticated, tools (PerioSafe/ImplantSafe with 
the quantitating Oralyzer reader) have been introduced and validated by different research 
groups. One of the advantages of this method is that samples of oral fluid can be collected 
non-invasively, and unusually high levels of aMMP-8 indicate that the active phase of peri-
odontal disease is in progress. 
The previously mentioned tool has been used successfully to identify active  periodontal 
tissue destruction, periodontitis, peri-implantitis and subclinical periodontitis – all forms 
of active periodontal disease (Nwhator et al. 2014, Al-Majid et al. 2018, Sorsa et al. 2016, 
Zhang et al. 2018, Raivisto et al. 2019, Sorsa et al. 2020). These terms are discussed in more 
detail in the methods and discussion section.
The periodontium is the tissue supporting the teeth; it consists of soft and hard tissues: 1) 
the gingiva, 2) the periodontal ligament, 3) the root cementum, and 4) the alveolar bone. 
Gingival tissues, which form a ring of masticatory mucosa around the teeth, protect against 
infection and friction caused by mastication. Healthy periodontal tissues are degraded 
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and repaired in a balanced manner so that the functional and structural integrity of the 
periodontium is preserved. The gingiva is composed of a densely collagenous tissue, the 
lamina propria, which contains blood and lymphatic vessels and nerves, supra alveolar 
fibres, and three types of epithelia. (1) The oral epithelium faces towards the oral cavity (2) 
the sulcular epithelium faces towards the teeth, and (3) the junctional epithelium (JE) is 
located in the area from the cementoenamel junction to the bottom of gingival sulcus; it is 
a thin and non-keratinised tissue with wide intercellular spaces through which inflamma-
tory cells can move (Nanci and Bosshardt 2006, Carranza et al. 2011). The cells of the JE’s 
internal basal lamina form the epithelial attachment to the tooth surface with junctional 
complexes called hemidesmosomes. The cellular turnover is high within the JE because the 
tissues are constantly remodelled (Nanci and Bosshardt 2006, Carranza et al. 2011). These 
allow neutrophils to transmigrate through the JE and reach the gingival crevice, creating 
a defensive barrier against microbes (Tonetti et al. 1998, Darveau 2010). Even if the peri-
odontium is healthy, around 30,000 neutrophils pass through the periodontal tissue every 
minute (Schiott and Loe 1970, Tonetti et al. 1998). People who have neutrophil deficiencies, 
whether acquired or congenital, are very likely to develop periodontitis (Hart et al. 1994).
The periodontal ligament, although proportionally small, has an important function. It 
forms a junction between two hard tissues; the teeth and the alveolar bone (McCulloch 
et. al 2000). Collagen type I is the main type of collagen in the periodontal ligament, and 
it is also considered to be the main substrate of MMP-8. Chewing forces are absorbed by 
the periodontal ligament, and nerve receptors within the ligament send feedback about the 
forces to the brain (McCulloch et al. 2000, Nanci and Bosshardt 2006). The periodontal 
ligament also supplies nutrients to the periodontium and plays a part in the remodelling of 
tissue, alveolar bone, and cementum. (Embery 1990, Nanci and Bosshardt 2006).
Cementum has the principal function of connecting the teeth to their surrounding alveolar 
bone. Cementum is not remodelled but a slow apposition continuously occurs in accor-
dance with physiologic demands. Alveolar bone is a relatively unstable structure; a charac-
teristic that may contribute to the pathogenesis of periodontitis. It has a high turnover rate, 
but when in a healthy state there is a balance between the resorption and formation of new 
bone. (Nanci and Bosshardt 2006). See figure (2) in Section 2.5 (Implantitis).
There is a multifactorial aetiology behind periodontitis, making it a complicated disease. 
Starting with gingival inflammation (gingivitis), which is mainly caused by bacteria adher-
ing to the tooth surface and forming colonies. It can be identified by redness, swelling and 
bleeding. Gingivitis is reversible with appropriate treatment. If gingivitis is left untreated, 
it can result in more severe inflammation, and the alveolar bone, periodontal ligament 
and tissues can begin to degrade and become irreversible. The key marker in the disease of 
gingivitis, when the disease is likely to transform to periodontitis, is when JE is converted 
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to epithelium pockets (Socransky et al. 1998). Periodontal pockets are the clinical sign of 
periodontitis. A periodontal pocket refers to abnormal sulcus depth between the tooth 
and periodontal tissues. It is formed when the sulcular epithelium migrates abnormally 
across the surface of the teeth. This pocket is conducive to the accumulation of biofilm 
and the growth of anaerobic bacteria. When gram-negative microbial plaques colonise the 
deepened gingival crevice, a chronic inflammatory response is initiated. In periodontitis, 
the subgingival biofilm, which in its healthy state is a symbiotic community dominated 
by gram-positive bacteria, is transformed to a dysbiotic state dominated by gram-negative 
bacteria. Particular species of bacteria are often observed together in subgingival plaque 
(Socransky et al. 1998). Among these species, there are some that are strongly associated 
with periodontitis, particularly the “red complex”, which includes P. gingivalis, T. denticola 
and Tannerella forsythia (T. forsythia). Although these bacteria are not necessarily the cause 
of the disease, they cause inflammation and periodontal pockets, which are favourable 
conditions for periodontitis-associated pathogens (Wade 2013, Hajishengallis et al. 2014, 
2015). 
Currently, scholars have found that there is a variety of microbiota found in periodonti-
tis, and red complex organisms are also present when there is no disease (Kononen et al. 
2007, Wade 2013). The existence of particular pathogens or a large amount of plaque do not 
seem to explain the severity of periodontitis experienced by individuals, but their response 
and susceptibility to the pathogens play a significant role. For instance, if one person is 
particularly genetically susceptible to the disease, tissue destruction can result from just a 
small amount of biofilm. Recent research has defined periodontitis as a polymicrobial dis-
turbance of host homeostasis (Darveau 2010), and pathogenesis has been described with a 
poly microbial synergy and dysbiosis model (Hajishengallis and Lamont 2012). 
These studies have reported that periodontitis is described by a synergistic and dysbiotic 
polymicrobial community, not simply the existence of bacteria, which have generally been 
termed as periodontal pathogens. Keystone pathogen hypothesis suggests that a number of 
pathogens, such as P. gingivalis, may be responsible for symbiotic microbial communities in 
the mouth being transformed into dysbiotic populations (Hajishengallis et al. 2012, 2015, 
Bosshardt and Lang 2005, Noh et al. 2013).
When dysbiotic microbes accumulate in the subgingival area, there is a corresponding pro-
liferation of key molecular patterns (pathogen-associated molecular patterns, or PAMPs) 
such as lipopolysaccharides (LPS), lipoteichoic acids, peptidoglycan and glucans, which the 
immune system recognises as threats (Hernandez et al. 2011, Yucel-Lindberg and Bage, 
2013). Host cells that have been attacked or injured by trauma or the invasion of bacte-
ria may secrete endogenous molecules known as danger-associated molecular patterns 
(DAMPs) to alert the immune system to the presence of danger (Jun et al. 2017). These 
signals are recognised by pattern recognition receptors (PRRs), the most important of 
which are toll-like receptors (TLRs). Patients with periodontitis show a higher expression 
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of TLR 2, -3, -4, and -9 in gingival tissue than healthy individuals (Rojo-Botello et al. 2012). 
PAMP/DAMP-PRR interaction results in the production of pro-inflammatory cytokines 
and the instigation of inflammatory reactions (Pollanen et al. 2012, Bosshardt et al. 2018). 
The presence of bacteria leads to the recruitment of neutrophils, which are the body’s first 
line of defence against bacterial proliferation (Wellappuli et al. 2018). The cells that form 
part of the immune system also secrete complement proteins (Olsen et al. 2017). These 
proteins contribute significantly to immune and inflammatory responses through adap-
tive and innate immunity. Some of them are also able to recruit neutrophils. While pro-
moting inflammation, some periodontal bacteria may not be killed by the neutrophils and 
may even cause the death of neutrophil cells, and thus, contribute to dysbiosis (Olsen and 
Hajishengallis 2016). 
If neutrophils, as the first line of defence against microbe invasion, fail in their function, 
greater numbers of chronic inflammatory cells such as macrophages and lymphocytes are 
recruited, thus extending the period of inflammation (Cortés-Vieyra et al. 2016). This is 
followed by several pro-inflammatory cytokines being released, including IL-6, IL- 8, and 
TNF-α (Noh et al. 2013). IL-8 is a strong chemoattractant cytokine, and when inflamma-
tion, occurs its function is to activate neutrophils. A number of different endothelial cells 
can release IL-8, including phagocytes, gingival fibroblasts, monocytes and neutrophils 
(Finoti et al. 2017). IL-1β is a pro-inflammatory cytokine and it has an important role in 
the regulation of the inflammatory response (Dinarello 2011). The expression of these cyto-
kines intensifies inflammation leading to even more tissue being destroyed (Pollanen et al. 
2012, Bosshardt et al. 2018). IL-1β has a number of functions. It increases the expression of 
intercellular adhesion molecule 1 (ICAM-1) in endothelial cells and mediates the secretion 
of chemokine (IL-8). Therefore, it facilitates neutrophils’ infiltration into the site of inflam-
mation. Bone resorption is induced by IL-1β, along with other proinflammatory cytokines 
and prostagaldin E2 (PGE2). Significantly elevated levels of IL-1β have been detected in 
periodontitis and peri-implantitis (Alexander and Damoulis 1994, Ghassib et al. 2019). 
IL-1β can induce MMP expression and production, particularly MMP-8 (Sasaki et al. 2000, 
Dinarello et al. 2011, Silva et al. 2015). TNF-α and IL-1β promote the secretion of IL-6, 
which is produced by a number of immune cells, such as dendritic cells, T-cells, macro-
phages and B-cells, in addition to resident cells such as fibroblasts, endothelial cells and 
keratinocytes. Osteoclasts also secrete IL-6, which stimulates bone resorption and osteo-
clast development. Patients with periodontitis show high levels of IL-6 in their GCF, tissues 
and cells (Guillot et al. 1995, Ghassib et al. 2019).
When periodontitis occurs, it results in dysregulation of the host immune response and 
disruption of tissue homeostasis. The first of these may originate from the challenge caused 
by the previously mentioned keystone pathogens and pathogenic microbial state, or immu-
noregulatory defects that can be caused by lifestyle habits, such as smoking, or condi-
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tions, such as diabetes. When dysbiotic microbiota are detected, as a defence against these 
microbes, the periodontal tissues express IL-8, intercellular adhesion molecule 1 (ICAM-1) 
and endothelial leukocyte adhesion molecule (E-selectin). These allow neutrophils to trans-
migrate through the JE and reach the gingival crevice, creating a defence barrier against the 
microbes (Tonetti et al. 1998, Darveau 2010, Loos et al. 2020). The increased production of 
cytokines, chemokines and proteolytic enzymes results in increased inflammation. Peri-
odontal tissue destruction is mediated mainly by neutrophils. Patients with periodontitis 
have been observed to have a large accumulation of neutrophils (Pollanen et al. 2012), but 
if there are too many neutrophils, this can cause periodontal tissue destruction through the 
release of degradative enzymes, such as MMPs, expressly MMP-8 and MMP-9 (Herr et al. 
2007, Sorsa et al. 2016, Morais et al. 2018), elastase, cathepsins, and cytotoxic substances, 
such as ROS. 
This in turn results in inflammation-mediated bone loss; RANKL is expressed and this 
induces osteoclastic bone resorption (Cortés Vieyra et al. 2016). In healthy tissue, MMPs 
and their inhibitors TIMPs, such as TIMP-1, play a significant role in the ECM homeo-
stasis. An imbalance between MMPs and TIMPs could lead to the destruction of tissue in 
inflammatory diseases, such as periodontitis and peri-implantitis where there is an increase 
in MMP expression and secretion, and a reduction in the levels of TIMPs (Offenbacher et 
al. 2007, Yucel-Lindberg and Bage 2013). As periodontitis progresses in the inflammation 
site, lymphocytes, macrophages and antigen-presenting cells (APC) also become active and 
transmigrate to the site of inflammation. The inflammation increases because inflamma-
tory cells and gingival epithelial cells express IL-1β, IL-6, and TNF-α. This results in the 
host cells secreting MMPs, which leads to the destruction of Booth soft and hard periodon-
tal tissues. Therefore, it can be concluded that host-derived factors bear primary responsi-
bility for the destruction of tissue in periodontitis (Darveau 2010, Hajishengallis et al. 2012, 
2015). See figure (1).
 
A number of risk factors have been established for periodontitis, including genetic factors, 
gender (with males being more susceptible), poor oral hygiene, elderly age, and smoking 
(Mantyla et al. 2003, Genco and Borgnakke 2013). It has also been suggested that systemic 
and other behavioural factors may play a role in this condition, for example, unhealthily 
diet, excessive alcohol consumption and stress. Certain medical conditions can contrib-
ute to the risk of periodontal disease, such as osteoporosis, obesity and diabetes. Many 
of these factors, e.g., stress, diabetes and smoking, do not act as initiators of the disease, 
but they alter the immune response of the host (Knight et al. 2016). The most common 
genetic factor linked to increased periodontitis susceptibility is polymorphisms in immune 
response genes (Loos et al. 2005). It is thought that genetics play a more significant role 
in aggressive and early-onset periodontitis compared to chronic periodontitis. The inter-
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Figure 1. The host response in periodontitis is a cascade process between cell types and 
inflammatory mediators, some of them are pointed in this figure. Notable are, cytokines and 
PGE2 affect the expression of RANKL, when the level of RANKL is increased, the OPG is not 
any more able to inhibit the interaction between RANKL and RANK, resulting in formation, 
activation of osteoclasts and alveolar bone degradation. TRAP-5 is secreted from osteoclasts as 
a consequences of bone resorption. IL, interleukin; PGE2, prostaglandin E2; PMN, polymor-
phonuclear leukocyte; MMP, matrix metalloproteinase; OPG, osteoprotegerin; RANK, recep-
tor activator of nuclear factor kappa-B; RANKL, receptor activator of nuclear factor kappa-  
ligand; TIMP, tissue inhibitor of metalloproteinase; TNF, tumor necrosis factor; TRAP, tar-
trate-resistant acid phosphatase. Figure modified after (Yucel-Lindberg and Bage, 2013).
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actions between all of the risk factors contribute to complex inter-relationships between 
them. One example is excessive alcohol consumption – this is linked to a low socioeco-
nomic status and poor oral hygiene and, therefore, it affects the immune response and the 
individual’s systemic health. As a result of this, it can be very challenging, if not impossible, 
to establish single risk factor-based causality (Heaton and Dietrich 2012). On a more seri-
ous note, periodontitis can have a negative impact on systemic health. Multiple studies have 
confirmed associations with conditions such as diabetes, cardiovascular diseases (CVD) 
and adverse pregnancy outcomes (Linden et al. 2013, Reyes et al. 2013, Kornman 2013, 
Morais et al. 2018, Chaparro et al. 2020).
Cytokines, such as TNF-α, IL-1β and IL-6, can be released by host inflammatory cells that 
have been stimulated by an inflammatory agent. This can result in the liver stimulation and 
the secretion of acute phase reactants; wherein C-reactive protein (CRP) is a primary reac-
tant. It was found that patients with periodontal disease had elevated plasma CRP levels 
following meta-analysis re-evaluation in a cross-sectional study. The researchers Paraskevas 
et al. (2008) agreed on this finding when comparing subjects with clinically healthy peri-
odontium. According to Vidal et al. (2009), it was made evident for the first time, following 
a recent randomised clinical trial, that non-surgical periodontal treatment led to decreased 
plasma CRP and IL-6 levels in patients suffering from severe periodontitis and severe 
non-responsive arterial hypertension. 
Heightened circulating MMP-8 levels have been linked to obesity, which emphasises the 
understanding that obesity may be a subclinical inflammatory condition (Lauhio et al. 
2016). Smoking also raises MMP-8 levels (Mantyla et al. 2006). Lauhio et al. (2016) have 
indicated that high MMP-8 levels in obese people may be a contributory factor in the 
advancement of insulin resistance, wherein cleavage of insulin receptors occurs. A syn-
thetic MMP-8 inhibitor can restrict this. Such results indicated MMP-8 to be a vital medi-
ator in the systemic inflammatory response linked to obesity, and therefore a potential 
drug target. The deployment of MMP inhibitors may reduce the long-term mortality that 
is linked to such subclinical inflammatory conditions. The cleavage of the human insulin 
receptor (INSR), which is instigated by MMP-8, can be restricted with synthetic inhibitors, 
such as doxycycline. 
According to studies carried out by Cervino et al. (2019), Fiorillo et al. (2019), elevated 
aMMP-8 levels were observed in diabetic patients (type 1 and 2), and both diabetes and 
pre-diabetes are very much linked to periodontal disease, gingivitis and periodontitis. Sep-
pala et al. (2006) have investigated how collagenase can be activated in diabetic patients’ 
GCF samples. Periodontal tissue destruction is strongly linked to insufficiently regulated 
diabetes, and when there are collagenases present in GCF, this effect can be both reflected 
and mediated. The study researchers have suggested that, if levels of blood glucose are diag-
nosed early and strictly regulated, this will contribute to controlling diabetic patients from 
contracting periodontal diseases. The study also indicated that periodontal tissue destruc-
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tion in people suffering from type 1 diabetes is likely to be mediated at least in part by 
active collagenases. 
Recent research by Grigoriadis et al. (2019) confirmed that, increased aMMP-8 levels are 
associated more often with pre-diabetic patients. The patients have been diagnosed by 
means of clinical protocol with chairside workflow to identify undiagnosed hyperglycaemia 
in periodontal clinics. The PerioSafe test produced contributory evidence that the clinical 
dental environment offers a good opportunity to screen for diabetes. An aMMP-8 test is a 
convenient and efficient method for identifying previously undiagnosed diabetes.
Some other biomarkers have received attention from researchers because of their signifi-
cant association with periodontitis and other systemic diseases. One of these biomarkers 
is asymmetric dimethylarginine (ADMA), which is commonly referred to in cardiovascu-
lar and hypertension research. In terms of periodontitis, this biomarker can be measured 
in both oral fluids and blood/plasma (Tsioufis et al. 2010, Isola et al. 2020). Macrophage 
inflammatory protein 1  (MIP-1  is another inflammatory biomarker, which has been 
studied in periodontitis in connection with systemic diseases (Al-Sabbagh et al. 2012). Oxi-
dative stress is defined as an increase in oxidant production or insufficient antioxidant pro-
duction. An imbalance of oxidants/antioxidants leads to excessive ROS generation, which 
can cause various forms of periodontal tissue destruction (Gumus et al. 2015). 
Vitamin C is an important nutrient, and it is acritical dietary oxidant in periodontal health. 
It acts as an anti-oxidant and reducing agent, which scavenges ROS, including free radicals. 
Vitamin C induces the differentiation of periodontal ligament progenitor cells by slowing 
and preventing the progression of periodontal disease. It has been recognised to prevent 
the oxidative activation of proMMP-8 through its connection to the oxidative MMP activa-
tion cascade (Suomalainen et al. 1991, Tomofuji et al. 2009, Tada and Miura 2019).
For the last 30 years, edentulous and partially edentulous patients have been offered alter-
native forms of implantology as treatment. In the last ten years, there has been an increase 
in the use of implants as abutments for fixed or removable prostheses. The reason for this is 
that they have superior function and aesthetics and can offer outstanding long-term prog-
nosis and durability. However, dental implants can still fail. If bone loss has occurred, the 
long-term prognosis of dental implant reconstructions are significantly reduced (Meffert et 
al. 1996, Xu et al. 2008). Figure (2).
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Figure 2. Differences between tooth and implant structures. Figure modified (Carrenza’s clini-
cal periodontology, 12th ED chapter 71, figure 71-16. Firolleni et al).
Peri-implant mucositis is defined as an inflammatory lesion of the mucosa adjacent to 
an endosseous implant with no associated bone loss. The two salient characteristics of 
peri-implant mucositis include the lack of peri-implant bone loss and inflammation in the 
peri-implant mucosa. Inflammation can be seen during a clinical examination because the 
tissue bleeds on probing, and there may also be signs of suppuration, swelling and ery-
thema (Lindhe et al. 2008, Heitz-Mayfield et al. 2010, 2018). 
On the other hand, while peri-implantitis also affects the tissue that surrounds dental 
implants, its main characteristics are inflammation in the peri-implant mucosa and bone 
loss. The inflammation can be detected as described above, however, radiographs are 
required to determine whether or not bone loss has occurred. In the same way that gingivi-
tis leads to periodontitis, it is assumed that peri-implant mucositis occurs before peri-im-
plantitis (Mombelli and Lang 1998, Lang et al. 2011, Schwarz et al. 2018).
Although peri-implantitis and periodontitis possess similar etiological factors and patho-
genesis, there is an important difference between the structure of the tissues surrounding 
an implant and that of the periodontium around natural teeth (Heitz-Mayfield et al. 2010). 
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Peri-implantitis and chronic periodontitis are associated with similar bacterial flora. Stud-
ies have found that there are high concentrations of gram-negative anaerobic bacteria and 
periodontitis-related pathogens in the vicinity of implants that show signs of peri-implanti-
tis (Sumida et al. 2002, Quirynen et al. 2006, Agerbaek et al. 2006).
The similarities in the aetiology and pathogenesis of periodontitis and peri-implantitis imply 
that there are more similarities than differences between the two diseases (Heitz-Mayfield 
et al. 2010). Both diseases are initiated by contact with a biofilm that holds pathogens, and 
both are associated with microbiota that have high gram-negative bacteria levels (Botero et 
al. 2005, Shibli et al. 2008, Tabanella et al. 2009). However, there is evidence to suggest that 
some instances of peri-implantitis involve the pathogen Staphylococcus aureus (S. aureus). 
Further research is required into the role played by S. aureus and other putative pathogens 
in peri-implantitis progression (Kronstrom et al. 2001, Botero et al. 2005). Although there 
are strong similarities between the response of the host to the bacterial challenge in gingivi-
tis and peri-implant mucositis, the inflammatory response to persistent biofilm accumula-
tion is more pronounced in peri-implant mucosal tissues than in dentogingival units. This 
could be due to differences in their structure including, for example, the ratio of fibroblasts 
to collagen, or vascularity. The “epithelial sealing” around both natural teeth and implants 
performs a similar function (Gould et al. 1984, Atsuta et al. 2015). Moreover, the structural 
differences that exist between teeth and implants have not been found to influence the host 
response to bacterial challenge (Zitzmann et al. 2001, 2002). 
Studies have shown that peri-implantitis and periodontitis lesions have many common fac-
tors (Konttinen et al. 2006, Berglundh et al. 2011, Belibasakis et al. 2014). Many inflam-
matory cells are infiltrated in the connective tissue situated next to the pocket epithelium, 
in particular plasma cells and B-lymphocytes. In both periodontitis and peri-implantitis, 
the upregulation of pro-inflammatory cytokines, such as IL-1β, IL-6, IL-8, and the TNF-α 
occurs (Duarte et al. 2009, Javed et al. 2011). However, one important difference has been 
reported where the infective lesions progress very rapidly and reach the alveolar bone 
marrow in certain stages of peri-implantitis. A recent study compared the two diseases 
and concluded that natural teeth had a “self-limiting” process in the surrounding tissues. 
During this process, “a protective connective tissue capsule of the tooth’s supracrestal gin-
gival fibres separating the lesion from the alveolar bone” is created. This did not occur in 
peri-implant tissues, where the lesion was able to spread to the bony crest (Zitzmann et al. 
2004, Berglundh et al. 2011). Therefore, we can make the reasonable assumption that in 
humans with peri-implantitis, there are destruction periods that are far more rapid than 
those seen in chronic periodontitis (Berglundh et al. 2011).
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In general, both periodontal and peri-implant treatment aims to re-establish the homeo-
static state, and thereby rebuild the reciprocally beneficial relationship between the com-
munity of microbes in the oral cavity and periodontal tissue (Khan et al. 2015). Treatment 
for periodontitis and peri-implantitis is based on removing the plaque retention and reduc-
ing the biofilm. Ultrasonic and manual instruments are utilised to debride the subgingival 
biofilm and granulated tissues using SRP (Sanz et al. 2012, Belibasakis et al. 2014). Chlor-
hexidine, a local antimicrobial agent, may also be administered. A new natural fermented 
lingonberry juice mouthwash has shown promising results in balancing microbial flora 
and decreasing the signs of inflammation (Parnanen et al. 2019). However, if bone loss has 
occurred and peri-implantitis has developed, non-surgical treatments are not effective. If 
the case is particularly severe, it may be necessary to prescribe surgical therapy or systemic 
antibiotics, although with caution in order to prevent antibiotic resistance (Herrera et al. 
2012). For periodontitis to be successfully treated and prevented from reoccurring, patients 
must be given instructions on how to maintain oral hygiene and, in the case of smokers, 
smoking cessation counselling should be offered. As a further preventative measure, and 
to maintain the positive outcome of treatment, patients must have regular appointments 
for receiving adjunctive periodontal therapy as the annual report of American Academy of 
Periodontology 2000 suggest. 
Increasing resistance to antibiotics encouraged researchers to find alternative procedures 
and different treatment strategies to avoid serious consequences (Isola et al. 2018). Med-
ications, such as tetracyclines, have also been found to inhibit MMPs (Golub et al. 2001, 
Emingil et al. 2004). Low-dose-doxycycline/sub-antimicrobial-dose-doxycycline (L/SDD) 
therapy aims to re-establish a balance between pro-inflammatory and anti-inflammatory 
mediators. Host modulation with L/SDD medication decreases gingival tissue and aMMP-8 
levels in oral fluid. It can also halt periodontal/peri-implant tissue destruction (Golub et 
al. 2016, Emingil et al. 2019). Doxycycline plays an essential role in MMP inhibition by 
means of the downregulation of gene expression, suppression of catalytic activity and halt-
ing oxidative activation (Uitto et al. 1994, Smith et al. 1999). Currently, L/SDD is the only 
MMP-inhibitory drug for humans that has been licensed by the US Food and Drug and 
Administration (US FDA) for the treatment of periodontal disease (Golub et al. 2016). The 
treatment consists of a 20 mg doxycycline dose, which is administered orally twice a day, or 
alternatively, a 40 mg dose once a day. The treatment produces serum levels of doxycycline 
that are too low to generate any antimicrobial effects, yet sufficient to inhibit/downregulate 
aMMP-8 (Sorsa et al. 2016). Compared to the higher traditional dose of 100 mg (once or 
twice daily), it is considered that L/SDD will not to result in bacterial resistance to doxycy-
cline, and it does not significantly alter normal flora, even following long-term daily intake 
(up to 24 months) (Golub et al. 2016). Furthermore, L/SDD significantly reduces inflam-
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matory mediator levels, aMMP-8, collagen degradation, pro-inflammatory cytokines, con-
nective tissue destruction in the periodontal region, and alveolar bone loss (Preshaw 2004, 
Preshaw et al. 2008). MMPs are considered to play a key role as mediators in periodontal 
tissue destruction (Kinane 2000, Sorsa et al. 2004, Kinane et al. 2017, Franco et al. 2017), 
and the irreversible connective tissue degradation seen in periodontitis has been reported 
to occur as a result of an imbalance between MMPs and their TIMP inhibitors (Sorsa et al. 
2004, 2016).
A biomarker is a parameter that evaluates and assesses the index of normal biological and 
pathological signs, and pharmacological therapeutic response (Strimbu et al. 2010). Making 
a physical examination of a patient’s periodontal and peri-implant tissues is time-consum-
ing and has to be carried out by well-trained dental professionals, which also makes it 
costly. Biomarkers are still required in periodontal disease; proper biomarkers should indi-
cate disease onset, current inflammatory activity levels and predict the future progression 
of diseases as opposed to radiographs, in which the visible damage could have been caused 
by a previous incident of periodontitis (Buduneli and Kinane 2011). The use of biomarkers 
could help to detect cases of periodontitis and peri-implantitis at an early stage and be used 
to determine how a patient is responding to treatment and which sites still contain active 
disease progression. On the other hand, the use of radiography and clinical examinations 
may not provide accurate results in terms of a patient’s susceptibility to periodontitis or 
how they are responding to treatment because some factors, such as microbial composition 
and host response, cannot be measured by these interventions although they play a signifi-
cant role in disease progression (Offenbacher et al. 2008).
Examples of biomarkers for the diagnosis of periodontitis and peri-implantitis are MMPs, 
host-derived markers, such as cytokines; tissue breakdown products, and markers derived 
from pathogens, such as bacterial DNA and proteases. Biomarkers in oral fluids, such as 
saliva, mouth rinse, GCF or PISF, can be easily collected. GCF and PISF are fluids derived 
from serum, which contain locally produced molecules, such as inflammatory mediators 
and by-products of tissue breakdown, and systemically derived markers (Recker et al. 2015, 
Barros et al. 2016). When inflammation occurs, the blood, GCF and PISF flows increase in 
the periodontal and peri-implant tissues, along with vascular permeability. Paper strips are 
usually used to collect fluid samples from gingival sulcus or periodontal pockets. Biomark-
ers in GCF or PISF reflect the status of a particular site in the mouth, whereas mouth rinse 
and saliva samples provide information on the overall oral status.
Comprehensive research has been conducted on biomolecules in oral fluids, to determine 
which ones could potentially be used as biomarkers in the diagnosis of periodontitis. It is 
difficult to specify a single marker of disease activity due to the complicated, multifactorial 
nature of periodontitis (Miller et al. 2006, Buduneli and Kinane 2011, Chojnowska et al. 
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2018). Biomarkers should meet a number of criteria: a) accuracy, b) reliability, and c) ther-
apeutic impact and usefulness for early intervention (Redberg et al. 2003). Biomarkers have 
the great advantage of being able to predict disease activity and they can be used to develop 
personalised medicine. They are valuable for identifying patients at high risk of a disease, 
and for predicting outcomes. All biomarkers need validation, and there is still debate as to 
which biomarker can be determined to be sufficient for clinical use (Lin et al. 2009). If they 
are being used as diagnostic tools, then their sensitivity and specificity must be assessed.
MMP-8 is an important contributor to the pathogenesis of periodontitis, and it can also be 
used as a biomarker for peri-implantitis (Sorsa et al. 2006, Al-Majid et al. 2018, Lupi et al. 
2019). There is evidence to show that tissue destruction of tissue occurring in periodontitis 
and peri-implantitis are mainly due to pathologically excessive collagenolytic activity. Col-
lagen is the major structural protein in periodontal tissues so, as expected, MMP-8 is the 
most neutral proteinase capable of initiating and stimulating the digestion of collagen type 
I, which is found in abundance in peri-implant and periodontal tissues (Ling et al. 2009, 
Arakawa et al. 2012, Leppilahti et al. 2014, Schmalz et al. 2019). 
MMP-8 can also play an important role as a diagnostic biomarker for peri-implantitis 
because it is the most predominant collagenolytic proteinase found in inflamed gingiva and 
GCF (Sorsa et al. 2016). In terms of evaluating inflammation levels and tissue destruction 
adjacent to implants, PISF may be able to offer a similar function as that of GCF in natural 
teeth (Alassy et al. 2019). Elevated MMP-8 levels, in particular in the active MMP-8 form, 
have been found to be linked to peri-implant and periodontal inflammation or disease, 
especially during the clinically active phase (Lee et al. 1995, Romanelli et al. 1999, Al-Ma-
jid et al. 2018). Suggestions have been made in regard to whether interstitial collagenase 
MMP-8 is the cause of periodontal and peri-implant degeneration, and active periodontal 
degeneration (APD) rather than bacterial enzyme (Sorsa et al. 1988, Izadi et al. 2015, Heik-
kinen et al. 2017) The level of active collagenase-2, MMP-8 (but not its latent form) can be 
used to predict and reflect the progression of peri-implant and periodontal disease (Sorsa 
et al. 2017, Morias et al. 2018). 
A number of studies have shown that in periodontitis patients, oral fluids contain higher 
aMMP-8 levels of than healthy controls (Lee et al. 1995, Morais et al. 2018). In addition 
to periodontitis, it has been recognised that in diseased PISF aMMP-8 levels are raised to 
pathological levels. It has also been reported that neutrophil collagenase or mesenchymal 
collagenase MMP-8 isoforms (particularly in active phases) exist in the PISF of peri-im-
plantitis patients. (Kivela-Rajamaki et al. 2003, Marcaccini et al. 2010, Mauramo et al. 2018, 




The time-resolved immunofluorometric assay, IFMA, with especific sensitive anti-MMP-8 
(Medix Biochemica Ltd, Espoo, Finland) established for detecting aMMP-8 has higher 
diagnostic accuracy than usually commercial MMP-8 ELISA, such as Amersham (GE 
Healthcare, UK) (Salminen et al. 2014, Leppilahti et al. 2014). Both, the enzyme-linked 
immunosorbent assay, ELISA, and IFMA are simple to perform, accurate, reproducible, 
and amenable to automation, however IFMA method appears to be more sensitive. A 
particular benefit of the IFMA technology is its large dynamic range (Marple et al. 2001). 
The IFMA selectivity technique recognises activated isoforms of MMP-8, particularly in 
the active aMMP-8 form (Al-Majid et al. 2018). On the other hand, usually commercial 
MMP-8 ELISA’s detect all MMP-8, including total and latent forms of MMP-8 (Sorsa et al. 
2010). 
IFMA results were found to correspond with DentoELISA; utilising the same aMMP-8 
antibody. But Lepplahti et al.’s study found it incompatible with Amersham ELISA; overall 
MMP-8 levels in the test were inconsistent with periodontal parameter values (Teronen et 
al. 1997, Leppilahti et al. 2011, Nwhator et al. 2014). Baeza et al. (2016) study found differ-
entiating periodontitis from healthy sites was less accurate when measuring aMMP-8 levels 
by means of IFMA. In contrast to other studies, DentoELISA was found to be compara-
ble to IFMA. There was a correlation between aMMP-8 levels when measured by means 
of IFMA and PD. IFMA and DentoELISA measurements showed an association between 
CAL and aMMP-8 (Baeza et al. 2016). The same aMMP-8 antibody utilised by DentoELISA 
and IFMA displays good cross-correlation with lateral-flow chairside/PoC PerioSafe and 
ImplantSafe immunotests both with and without the quantitative Oralyzer reader (Ram-
seier et al. 2016, Sorsa et al. 2017, Rathnayake et al. 2017).
Several kits, which have been designed to discern oral fluid biomarkers using a variety of 
techniques, identify particular periodontopathogens or carry out an enzymatic reaction of 
these pathogens, have been created for commercial use commercially or for model-testing. 
PerioGard, the commercial test kit for measuring aspartate aminotransferase (AST) activity 
in GCF, aims to give a positive test result concerning GCF AST activity ≥ 800 μl/U wherein 
the result appears as a colour change after 15 min. The test cannot differentiate well between 
sites with severe inflammation (Persson et al. 1995, Chepuri et al. 2015).
PocketWatch is a different test, which is used to assess AST levels. The test can detect 
destructive periodontal pockets and it can also be used for assessing treatment plans. The 
assessment results can be helpful in clinical reviews of periodontal disease locations (Shi-
mada et al. 2000, Chepuri et al. 2015).
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The Periocheck kit is used to detect non-specific neutral proteases and increased proteo-
lytic activity in GCF. The baseline sensitivity for Periocheck was 88% with a specificity of 
61%. Therefore, it could not be considered as a reliable reflection in clinical periodontitis 
measurement (Hemmings et al. 1997).
Perioscan is also a chairside test, which has been devised for detecting a group of periodon-
topathogens, P. gingivalis, T. denticola and T. forsythus as well as the trypsin-like enzyme 
produced by pathogens. The sensitivity and specificity of the test were 99% and 55% respec-
tively (Hemmings et al. 1997, Chepuri et al. 2015).
A description of a chairside assay for calprotectin in GSF has also been developed and the 
test is reliable for diagnosing periodontal diseases. However, it does not have the ability to 
reflect the the disease severity and activity while there is no substance degradation caused 
by calprotectin (Kido et al. 2017).
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The hypothesis of the study was that PerioSafe and ImplantSafe tools with the quantita-
tive Oralyzer reader would be accurate in the detection and prediction of periodontal and 
peri-implant diseases. We also hypothesised the reliability and efficacy of aMMP-8 Peri-
oSafe test with Oralyzer for grading and staging purposes in the new periodontal classi-
fication system. We also assumed the ability of proteome approach (LFQ) for measuring 
different biomarkers in saliva in order to compare these results with traditional immuno-
assay-based methods. Finally, we hypothesised the effectiveness of SDD therapy for some 
inflammatory biomarkers and periodontal clinical parameters. 
In the process of achieving these objectives, the study was divided into five more specific 
goals: 
1. The aim of study I was to examine the MMP-8 expression and activation in estab-
lished gingivitis and to validate LFQ in comparison to antibody-based immunoassays 
methods. 
2. Study II had two main objectives. First, it used PerioSafe and ImplantSafe with the 
Oralyzer reader to determine how well healthy and diseased patients could be differ-
entiated on the basis of aMMP-8 expression, and whether it could be used to assess the 
treatment efficacy. Secondly, IFMA and zymography methods were used in PISF sam-
ples to evaluate how well healthy and diseased patients could be differentiated.
3. Study III evaluated the aMMP-8 PoC test, PerioSafe with the Oralyzer reader, in the 
new periodontal classification system (stage/grade) that was published in 2018 in order 
to compare the effectiveness of the PerioSafe system with traditional BOP and PI meth-
ods. It also compared mouth rinse and saliva to determine which of the two was the 
most sensitive for detecting aMMP-8. 
4. Study IV aimed to assess the utilisation of GCF and saliva in the PoC aMMP-8 test for 
the purpose of diagnosing and differentiating healthy sites, gingivitis and periodontitis 
in line with the new global classification of periodontitis. The IFMA method was used 
quantitatively in GCF and saliva samples to show the sensitivity of aMMP-8 detection 
in both samples.
5. Study V aimed to assess how effective SDD is when combined with non-surgical peri-
odontal therapy. The results were compared to results of non-surgical periodontal 
therapy when not combined with SDD. It investigated the effects of these therapies 
over a period of twelve months. The study focused on GCF biomarkers, such as MPO, 
MMP-9, MMP-13, OPG, and TRAP-5 by ELISA, and MMP-8 by IFMA, for periodon-
tal tissue catabolism that are linked to clinical outcomes. 
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This is an experimental gingivitis model; the participants for this study (n=10) were selected 
from a larger study on human gingivitis, which was carried out by the Department of Den-
tistry and Oral Health, Aarhus University 2015–2016 (Nascimento et al. 2019). There were 
three phases in the model. The first phase (14 days prior to the start date of second phase 
(day 0)) included recruitment and oral hygiene practices. From day 0 to day 21, during the 
second phase, dental plaque was induced by omitting any oral hygiene-related activities. In 
the third and final resolution (R) phase, from day 21 to day 35, oral hygiene practices were 
resumed to remove the plaque. 
The participants were all 18-35-year-olds and the inclusion criteria for the study included ≥ 
20 teeth, PD ≤4 mm and interproximal CAL <2 mm. Levels of plaque and gingival inflam-
mation were measured and recorded according to the modified Quigley and Hein plaque 
index (TQHPI) and the modified gingival index (MGI) respectively. TQHPI is an index 
that measures the plaque disclosed on the unrestored teeth’s buccal and lingual surfaces at 
a scale of 0 to 5, as described by (Quigley et al. 1962) and updated by (Turesky et al. 1970). 
An index is specified for the entire mouth, except for the third molars, by dividing the total 
score by the number of examined surfaces. MGI was developed by Lobene et al. (1986). An 
index was used for visually measuring the incidence and severity of gingivitis without any 
invasive measures. 
Exclusion criteria included pregnancy, breastfeeding, having taken antibiotics or anti-in-
flammatory drugs in the past 6 weeks before the study began, smoking and diseases that 
affected the immune system. No stents were applied. In this longitudinal study, we analysed 
unstimulated whole saliva samples for the total protein concentration using a Qubit protein 
assay to identify four biomarkers, including MMP-8, TIMP-1, MPO and PMN elastase by 
means of LFQ, time-resolved IFMA (MMP-8) or different ELISAs the others. Additionally, 
molecular forms of salivaryMMP-8 were assessed with Western blots.
This was a case-control study, which was divided into two parts involving three groups: 
periodontitis and peri-implantitis with healthy control participants. The periodontal status 
for both participants with periodontitis and healthy controls was assessed by means of e.g. 
CAL, PD, BOP, PI and radiographic X-ray examinations. The inclusion criteria for the first 
part of the study included at least five sites with PD ≥4 mm, no history of systemic disor-
ders, no history of antibiotics or anti-inflammatory drugs in the past six months and no 
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history of periodontitis treatment in the past six months. The three groups consisted of 10 
chronic periodontitis patients, 30 peri-implantitis patients, and 10 and 30 healthy control 
subjects corresponding to the two previously mentioned groups. The group of patients with 
chronic periodontitis, aged 34 – 73 years), consisted of 8 men and 2 women. Healthy con-
trols were periodontally and systemically healthy dental students (22–24-year-olds). The 
10 periodontitis patients and the 10-dental student (control subjects) were Finnish, while 
the 30 peri-implantitis patients and 30 peri-implant healthy control subjects were Swed-
ish.  After baseline examination, mouth rinse samples were examined using PerioSafe to 
detect aMMP-8. The visual PerioSafe test was initially used, followed by the quantitation of 
aMMP-8 lateral-flow test-sticks with the Oralyzer reader. After that, periodontal treatment 
scaling and root planning was done in conjunction with anti-infective therapy. Six weeks 
after treatment, the patients underwent clinical follow-up checks and new PerioSafe tests 
were completed to determine the effectiveness of the aMMP-8 PerioSafe test before and 
after treatment.
In the second part of this case-control study, clinical examinations included CAL, PD, BOP, 
PI, and X-rays were used to diagnose healthy and peri-implantitis sites. The inclusion cri-
teria included at least PD ≥4 mm, BOP, detected alveolar bone loss around the implant in 
the peri-implantitis site, no history of antibiotics or anti-inflammatory drugs in the past six 
months. The peri-implantitis patients included 14 men and 16 women in the age group of 
39-79-year-olds, while the healthy participants included 23 women and 7 men. After base-
line examination, the ImplantSafe aMMP-8 PoC/chairside PISF test was used to identify 
peri-implantitis sites (n = 29) so that they could be differentiated from clinically healthy 
peri-implant sites (n = 32). One peri-implantitis sample was missing, and two healthy con-
trols were added for certainty. The peri-implantitis sites were treated surgically. A follow-up 
was carried out 3 – 6 months after treatment was administered and a new ImplantSafe 
aMMP-8 test was completed. The quantitative analysis of aMMP-8 in PISF samples was also 
carried out by means of IFMA, and MMP-9 gelatinolytic activity was analysed by quantita-
tive gelatin zymography.
This study was performed in collaboration with Aristotle University, Assoc. Prof Dimitra 
Sakellari. One hundred and fifty participants, consisting of patients and control subjects, 
were examined at the Periodontology Aristotles University Clinic, Thessaloniki, Greece. 
Patients were selected for testing according to the screening questionnaire completed by the 
Centers for Disease Control and Prevention (CDC) USA (Grigoriadis et al. 2019). Partic-
ipants were 25-78 years old; 74 were men and 76 women. Their aMMP-8 levels were mea-
sured with a PerioSafe test and BOP, CAL and VPI results were assessed using the new clas-
sification system (Stage I to III and Grade A to C) (Tonetti et al. 2018). Six surfaces of each 
tooth were assessed using an automated probe (Florida probe, Florida Probe Corporation, 
Gainesville, FL, USA). A full clinical examination was initially carried out for each patient 
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in order to evaluate their oral health and signs of periodontitis. After that, the aMMP-8 
mouth rinse test by PerioSafe was completed. Inclusion criteria included not taking certain 
medications such as anti-inflammatories or antibiotics for three months before the study 
and having no underlying diseases.
We used PerioSafe with the quantitative Oralyzer reader for all 150 participants to measure 
the aMMP-8 levels in mouth rinse samples. In the same way, we analysed the aMMP-8 
levels in saliva using IFMA to show the efficacy and accuracy of both samples among the 
150 Greek patients.
This is a cross-sectional study carried out in collaboration with Prof Gulnur Emingil, Ege 
University, Medical School, Izmir, Turkey. This study engaged 80 participants; 18 of them 
had Stage III periodontitis; 19 had Stage IV periodontitis; a further 21 had gingivitis, and 
the remaining 22 had clinically healthy periodontium. Inclusion criteria for participants 
were the following criteria; they had to be free of systemic diseases, including diabetes, car-
diovascular conditions and immune system disorders. They were also barred from partic-
ipating if they regularly took medication that might impact the periodontal tissues, if they 
had taken antibiotics in the 10-week period before the study, if they were pregnant or if 
they smoked. Classification of the subjects matched the most recent periodontitis classifica-
tion, and the people taking part had to provide written consent. 
Four classifications were created in regard to their periodontal condition: (1) A group in 
good health, in which the subjects had PD <3 mm, no gingival recession as there was no 
adverse periodontal effect, and CAL <2 mm with BOP <10% of full-mouth score examina-
tion; (2) The group suffering from gingivitis had different levels of inflammation, they had 
CAL < 2 mm, but radiographic bone loss as a result of periodontitis was not detectable. If 
the patient was suffering from interdental CAL, which could be identified in  at least two 
non-adjacent teeth, they could be considered to have periodontitis; (3) The subjects in the 
P-Stage III group, whose PD >6 mm combined with vertical bone loss >3 mm, had Class 
II or III furcation involvement with medium-level ridge abnormality; (4) The final set of 
subjects – the P-Stage IV group – suffered from impaired function in the form of mastica-
tion, secondary occlusal trauma and breakdown of posterior bite abilities. The PD, CAL, 
papillae-bleeding-index (PBI) (Saxer, & Mühlemann, 1975) and PI data were noted at six 
locations for each tooth. A manual periodontal probe was used to perform PD and CAL 
analysis. Chairside/PoC analysis of aMMP-8 levels in GCF and saliva was carried out; the 
analysis was conducted by means of both a lateral-flow immunotest and IFMA to assess the 
accuracy of the test among the participants.
This is a clinical randomised follow-up study, which involved a double-blinded, place-
bo-controlled adjunctive SDD trial that took place over a period of 12 months. Participants 
included thirty 31-61-year-old patients with chronic periodontitis (stage III) (Tonetti et 
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al. 2018) from the Department of Periodontology, Dentistry School, Ege University, İzmir. 
The participants were recruited between the years 2002-2004. The study was divided into 3 
phases: screening, treatment and evaluation. First, the participants were recruited and their 
eligibility was checked. During the first stage of the study, the patients’ periodontal status 
was assessed. A standard manual probe (Williams probe) was used to take measurements 
at six sites around each tooth. Full mouth PD, CAL, GI and PI scores were recorded. The 
dental and medical histories of the participants were taken, and results of X-ray examina-
tions, clinical findings and periodontal history were used for the diagnosis of periodontitis. 
Information on the treatment selected for patients was kept blinded for the last part of the 
study. The subjects were then randomised in to two groups: SDD (n = 15) or placebo (n = 
15).
The baseline examination was used to collect GCF samples and the same clinician per-
formed non-surgical periodontal therapy over several sessions. A local anaesthetic was 
used to clear tooth and root surfaces of all deposits. During each session with the clini-
cian, all of the patients were instructed on how to brush their teeth and use interdental 
floss or brushes. For 3 months, the placebo group took a placebo capsule that contained 
starch while the SDD group took adjunctive SDD (20 mg per capsule). The capsules for 
each group were identical in appearance. Both groups were advised to take one capsule 
in the morning and one in the evening, an hour before eating. They were anonymised by 
being allocated a code number. In order to encourage compliance with the instructions, the 
participants were given 28 capsules every 2 weeks.  
The participants were evaluated 4 times after the baseline examination. The first time was 
after 3 months, at the end of the SDD or placebo therapy, and the following evaluations 
took place at 6, 9 and 12 months. At each of these visits, GCF sampling was completed and 
clinical parameters were assessed. The participants also received maintenance therapy at 
each visit, and they were encouraged to continue with their oral hygiene routine.
The inclusion criteria included having at least 14 teeth. Periodontitis is also diagnosed 
through buccal or oral CAL ≥3 mm with pocketing >3 mm detectable in ≥2 teeth. Exclu-
sion criteria included being pregnant or breastfeeding, or excessive smoking or alcohol 
consumption. Participants were also excluded if they had used antibiotics, other medicines 
or treatment for periodontitis within the past four months, or if they were hypersensi-
tive to any form of tetracycline. Participants could also not have a history of any systemic 
disease. The purpose of the study was explained to the participants and they all provided 
informed consent. In this longitudinal study, we analysed MPO, MMP-9, MMP-13, OPG, 
and TRAP-5 in GCF using ELISA, and MMP-8 using IFMA analysis.
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Patients who were recruited for dental examination between 8 am – 10 am were asked to 
refrain from normal cleaning practices, such as brushing and flossing, as well as rinsing. 
They were also asked not to drink for two hours before providing a sample (Papagerakis et 
al. 2019). GCF samples were collected from mesiobuccal sites of single-rooted teeth with 
probing depths of 6–8 mm using rotating quadrants for each participant. A curette was 
used to remove supragingival plaque from the interproximal surfaces before sampling took 
place. An air syringe was used to dry the surfaces and they were separated with cotton rolls. 
In study IV, the aMMP-8 pool rapid test comprised of a dipstick test in protective foil, GCF 
collection strips and a tube with an elution buffer. The GCF strip was slid into the gingival 
crevice to a depth of just one or two mm, so as to not harm the soft tissue. The strip was left 
in place for 30 seconds, then removed and placed into an elution buffer tube. The specimen 
of elution fluid was kept for further analysis at a temperature of -80ºC. In study V, a GCF 
strip (ProFlow, Inc., Amityville, NY, USA) was used to collect GCF. Care was taken when 
inserting the paper so as to avoid mechanical damage to the teeth. Any strips contaminated 
with blood were thrown away. In study V, an electronic device (ProFlow) was employed to 
measure the absorbed GCF volume of each strip. The strips were stored at -80ºC., in sterile 
polypropylene tubes, until they were required for analysis. A standard curve was used to 
convert the readings from the Periotron 8000 into actual volumes (μl). 
In study I, 210 unstimulated whole saliva samples were collected as samples. The saliva 
samples were collected from 42 participants five times (on days 0, +7, +14, +21 and +35). 
In study III and IV, unstimulated saliva samples were also collected. Participants had to 
have been fasting for 2 h before the samples were taken between 8 am – 10 am. Participants 
were told to rinse their mouth with tap water twice and wait five minutes after rinsing, 
before saliva collection, to prevent any dilution. Samples were stored at -80°C until they 
were required for analysis (Papagerakis et al. 2019). 
Mouth rinse and PISF collection samples have been further defined in the following section 
concerning PerioSafe and ImplantSafe tests (4.3.2).
 
A lateral-flow sandwich immunoassay is based on the utilisation of monoclonal antibod-
ies conjugated to latex particles. The results from the immunochromatographic chairside 
dip-stick test (Mantyla et al. 2003) are ready in five minutes. Sorsa et al. (1999) outlined 
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the test’s principle, while the clinical testing protocol was described by Mantyla et al. 
(2003). The dipstick test was immersed in an elation buffer for five minutes, and the result-
ing colour change showed one or two lines. The test allowed aMMP-8 concentrations in 
the GCF specimens to be discerned. The fundamental idea of the test (aMMP-8 dip-stick, 
Perio Safe and ImplantSafe) was to determine if the sample contains aMMP-8 on the basis 
of antibodies attached to latex particles. The particles are carried by the liquid flow along 
the test stick passing over the catching zone containing the other MMP-8 antibody. A blue 
line will appear indicating a positive result while a negative result is indicated by no line. 
The correct performance of the test is indicated by the appearance of a second blue line. 
20 ng/ml is considered the cut-off mark for the PoC test; this point has been indicated to 
correspond with the visual aMMP-8 PoC test. Proteins emanating from the GCF travel to 
the buffer, which then moves down the dip-stick and adheres to the blue, antibody-labelled 
latex fragments on the stick. If there is enough aMMP-8 present, the saliva reveals a blue 
line. The test is assessed visually and can be considered as valid if a blue line emerges within 
five minutes. Two lines (test and control) mean that the dipstick reads a positive result; one 
line is considered negative. 20 ng/ml is considered the cut-off mark for the PoC test; this 
point has been indicated to correspond with the visual aMMP-8 PoC test.
Based on the invention by Prof Timo Sorsa, recent lateral-flow PoC PerioSafe and 
ImplantSafe tests, which originate from Finland and further expanded upon in Germany, 
have been developed on the basis of earlier technologies, and monoclonal antibodies (Man-
tyla et al 2003, Sorsa et al. 2017). Medix Biochemica Ltd (Espoo, Finland) and Dentognos-
tics GmbH (Jena, Germany) have developed PerioSafe and ImplantSafe and the Oralyzer 
reader, which are commercially available (Sorsa et al. 2017).
PerioSafe is a mouth rinse test, which can be administered to patients by following the 
manufacturer’s instructions. The procedure begins with a 30-second prerinse with tap 
water. There is then a wait of 30 seconds, followed by rinsing for a further 30 seconds with 
the (aqua purificata) test liquid. The next step involves pouring the mouth rinse into a small 
collection beaker included in the test kit. A syringe, again part of the test kit, is used to draw 
of three millilitres of the rinse. A filter is then placed on the syringe, whereupon a maxi-
mum of four drops are placed on the test stick of a lateral-flow immunoassay system. The 
result is visible after five minutes when the test stick provides visual results in the form of a 
colour change, where one blue line indicates a negative (no-risk) result, and two blue lines 
show a positive (increased risk) result for periodontitis.
ImplantSafe is used in dental implantology as a rapid lateral-flow chromatography immu-
notest. It is a modern, in-vitro diagnostic dip-stick test based on lateral-flow sandwich 
immunoassay. Highly specific monoclonal antibodies MoAB 8706 and MoAB 8708 are used 
in the PerioSafe as antibodies conjugated to latex particles. A sterile PISF collection strip, 
part of the test kit, is used to collect the sample atraumatically directly from the implant 
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sulcus. To avoid any bleeding from the marginal gingiva, the tip of the collection sampling 
strip for absorbing PISF is placed into the gingival sulcus for 30 seconds. It is then placed in 
a test tube containing a buffer solution. The ImplantSafe dip-stick is immersed in the tube 
for 15 seconds and then left for five minutes. 
The Oralyzer reader can then be used to perform a quantitative analysis of both PerioSafe 
and ImplantSafe tests. An increased risk of periodontitis or peri-implantitis is evident even 
if the second line is less pronounced. After five minutes, a PoC chairside diagnosis of the 
PerioSafe and ImplantSafe test sticks can be quantitated using the digital Oralyzer reader. 
The reader has two compartments for both different sticks. The test stick is placed in the 
appropriate compartment of the reader, the cover is closed, and the compartment is pushed 
into the Oralyzer and the check mark is pressed. The levels of aMMP-8 are measured auto-
matically by the Oralyzer’s mechanism in five minutes. The results of the qualitative visually 
assessed plus/minus test are expressed quantitively in ng/ml aMMP-8 PoC/chairside. As 
stated, the cut-off value (detection limit) for both tests is (20 ng aMMP-8 per ml). A pos-
itive result, indicating normal conditions and a healthy status (<20 ng aMMP-8 per ml) is 
depicted by a single line, whereas two lines indicate an increased risk of periodontitis or 
peri-implantitis (≥20 ng aMMP-8 per ml). See figures (3 and 4).
Figure 3. The PerioSafe kit contains an aMMP-8 immunotest including a filtered syringe, test 
liquid (aqua purificata), lateral-flow immunoassay sticks, and a test liquid/mouth rinse collec-
tion cup. (A) two lines indicate a positive result, which means the patient is at high risk of peri-
odontal tissue destruction with ≥20 ng/ml. (B) one line indicates a negative result, which means 
the patient is not at risk of periodontal tissue destruction with <20 ng/ml.
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Figure 4. 1. The ImplantSafe kit contains a dip-stick test, PISF collection strip and 600 μl elution 
buffer. (2) results are ready in 5 mins and the appearance of a single line indicates low aMMP-8 
in PISF, and no risk of peri-implantitis. (3) The appearance of two lines in the result indicate 
elevated aMMP-8 levels in PISF and an increased risk for peri-implantitis and collagenolytic 
activity. (4,5) The Oralyzer reader, which quantitates test results within 5 min; <20 ng/ml refers 
to no risk of peri-implantitis and ≥20 ng/ml refers to an increased risk of peri-implantitis.
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GCF, gingival crevicular fluid; PISF, Peri-implant sulcular fluid; MMP-8, Matrix Metallo-
proteinase-8; MPO, myeloperoxidase; OPG, osteoprotegerin; TRAP, tartrate-resistant acid 
phosphatase; ELISA, Enzyme-Linked Immunosorbent Assay; LFQ, label-free quantita-
tive proteome; IFMA, time-resolved immunofluorometric assay; TIMP, tissue inhibitor of 
matrix metalloproteinases; PMN elastase, polymorphonuclear leukocyte elastase.
A time-resolved immunofluorometric assay (IFMA) determined the active MMP-8 con-
centrations. The catching and tracer antibodies that were used were monoclonal MMP-8-
specific 8708 and 8706 antibodies, which were supplied by (Medix Biochemica Ldt, Espoo, 
Finland) (Hemmilä et al.1984). The assay buffer contained 20 mM Tris-HCl, pH 7.5, 0.5 
M NaCl, 5 mM CaCl2 50 μM ZnCl2, 0.5% bovine serum albumin, 0.05% sodium azide and 
20 mg/l diethylenetriaminepentaacetic acid (DTPA). Once diluted in the assay buffer, the 
samples were incubated for one hour. Thereafter, they were incubated for one hour with a 
tracer antibody, labelled with Europium, followed by the addition of an enhancement solu-
tion. An EnVision 2105 multimode plate reader (PerkinElmer Finland, ex. Wallac, Turku, 
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Finland) 1234 Delfia Research Fluorometer (Wallac, Turku, Finland) was used to measure 
fluorescence after five minutes. The detection limit for the assay is 0.08 ng/ml (Hemmila et 
al. 1984, Hanemaaijer et al. 1997).
The quantification of the chosen protein concentration was carried out using ELISA. In our 
studies, we used the following commercial ELISA kit for the saliva and GCF quantification 
according to the manufacturer’s guidelines on diluted samples:
In study I, we used saliva samples:
• TIMP-1 (Amersham Biosciences Ltd, Buckinghamshire, UK)
• MPO (Immundiagnostik AG, Bensheim, Germany)
• PMN elastase (Bender Med Systems mbH, Vienna, Austria)
In study V, we used GCF samples:
• MMP-9, MMP-13 (Human Biotrak, Healthcare and Amersham, Little Chalfont, UK)
• MPO (Immundiagnostik AG, Bensheim, Germany)
• OPG and TRAP-5 (Milliplex MAP multiplex assay panel, Darmstadt, Germany)
The main procedure was that concentrations were measured using pre-coated wells (96-
well microplates) by adding samples, standards and controls at room temperature for an 
incubation time of 1-2 h depending on each protocol of the shaker. Thereafter, aspiration 
and standard washing was carried out 4 times with wash buffer, unbound protein was wiped 
away and the bound protein was identified by pipetting a peroxidase-conjugated secondary 
anti-antibody (specific towards the desired protein). This was followed by, 1 h incubation 
time on the shaker, and aspiration and washing 4 times with a wash buffer. Subsequently, a 
TMB substrate, which was developed using hydrogen peroxide and tetramethylbenzidine, 
was placed on the shaker for 30 minutes. The corresponding solution was added to all the 
wells to stop the reaction. A wavelength of 450 nm was used to measure the optical density 
with a Victor X4 Multilabel Reader (PerkinElmer Finland Oy, Turku, Finland). Based on 
measured standards, the calibration curve was drawn and used to calculate the concentra-
tion of the measured protein. The detection limit was agreed on the basis of each Elisa kit 
used. 
The other ELISA kit was used to detect OPG and TRAP-5 in a quantitative sandwich-based 
multiplex ELISA array according to the manufacturer’s instructions. Briefly, a Luminex 
platform was used to inspect data. The basis of this quantitative immunoassay is the util-
isation of colour-coded magnetic microspheres with fluorescent dyes; each dye has been 
coated by a specific capture antibody. Following the bead capturing an analyte, a bioti-
nylated detection antibody is added, which is then incubated with the reporter molecule, 
streptavidin-phycoerythrin (PE) conjugate. The microspheres then transit through a laser; 
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this excites the internal dyes that mark the microspheres, while a further laser excites the 
PE, which is the fluorescent dye on the reporter molecule. Lastly, each microsphere is iden-
tified by signal processors that quantify the outcome using the fluorescent reporter’s signals 
that utilise a standard curve. 
In study II, gelatin-substrate zymography was used with PISF samples to analyse gelati-
nolytic activity, particularly for MMP-9. Kupai et al. (2010) noted that this is based on the 
molecular weight to differentiate the latent and active forms situated in the different molec-
ular weights. The technique used is based on sodium dodecyl sulfate and polyacrylamide 
gel electrophoresis (SDS-PAGE). Briefly, samples were mixed with Laemmli’s buffer with a 
2 h incubation time and without any reagent reduction. The enzymes were denaturated and 
inactivated by the SDS treatment buffer. After that, to renaturate the enzyme, the gels were 
then washed two times for 30 min with 50 mM Tris-HCl buffer solutions. The solutions had 
a pH 7.5, containing 2.5% Tween 80 and 0.02% NaN3. Furthermore, the second wash was 
mixed with 0.5 mM CaCl2 and 1 μM ZnCl2. Finally, the gels were incubated overnight at a 
temperature of 37°C in a 50 mM Tris-HCl buffer, pH 7.5, containing 0.02% NaN3, 0.5 mM 
CaCl2, and 1 μM ZnCl2. The gels were then stained with 1% Coomassie Brilliant Blue R-250. 
MMP activity could be detected as digested zones in the gel, and gelatinolytic activity inten-
sities were quantified using a Bio-Rad Model GS-700 imaging densitometer.
Immunoblotting is a frequently used laboratory method to identify and separate proteins 
based on molecular weight forms by using a specific antibody. The enzyme of particular 
interest in this study is MMP-8. The sample, in this instance, was mixed with Laemmli’s 
buffer without any reagent reduction, and boiled for three to five minutes. Then, by type, 
samples were pipetted to polyacrylamide gels. During gel electrophoresis, the protein in 
our saliva samples were separated on the basis of molecular weight. After that, the protein 
were transferred to a nitrocellulose membrane and 5% skim milk in Tris-buffered saline, 
and 0.1% Tween 20 and 0.05% Triton X-100 were used to block the non-specific binding 
site of the membrane for one hour. This was followed by four 15-minutes washes, making 
a total of one hour. The membrane was then incubated overnight at room temperature on 
a shaker with primary antibody labelling specific to MMP-8. Only the antibody bound to 
the membrane was left after washing four more times, each of 15-minute duration, making 
a total of one hour. The secondary antibody was then added for one hour. The secondary 
antibody is conjugated to an enzyme or other material that enables the protein of interest to 
be detected and to appear as a band on the blot. The amount of protein present is indicated 
by the thickness of the band. The film is then developed to find the bound antibodies. A 
Model Bio-Rad GS-700 Imaging Densitometer (Bio-Rad Laboratories, Hercules, CA, USA) 
was used to evaluate the intensity of different MMP-8 molecular weight forms.
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The term of ‘proteome’ is used in the field of mass spectrometry (MS) -based proteomics 
to show the currently unachieved goal of identifying all proteins of a species (Beck et al. 
2011). Proteomics, common in medicine and dentistry, is the study of proteomes, which 
is the entire set of proteins that is, or can be, expressed by a genome, cell, tissue, or organ-
ism at a certain time. Technological advances include the study of saliva as a non-invasive 
means of analysing systemic health. Over 5,000 proteins can be identified through saliva. 
However, progress in characterising and validating them further is hampered by the pau-
city of antibodies, which have high specificity for all of them (Beck et al. 2011, Megger et al. 
2013, Bostanci et al. 2017, 2018).
Despite the success of un-targeted proteomics in identifying several different potential bio-
markers, to date, none have been found applicable for clinical application for periodontal 
diagnostics purposes. However, available tools have identified several candidate markers 
that are better characterised and utilised. To date, the main source for protein quantification 
using antibodies to specifically target a protein of interest, is by means of antibody-based 
immunoassays (Aebersold et al. 2003, Bostanci et al. 2017, 2018).
The following elemental stages are included in label-free quantitative proteomics. Firstly, 
sample preparation, which includes protein extraction, reduction, alkylation and digestion; 
then, sample separation by liquid chromatography (LC) or two-dimensional liquid chro-
matography (LC-LC), and analysis by tandem mass spectrometry (MS/MS); and finally, 
data analysis including peptide/protein identification, quantification and statistical analysis.
Each sample is prepared separately for the label-free quantitative method. Thereafter, they 
are subjected to individual LC-MS/MS or LC/LC-MS/MS runs. Normally, there are two 
categories of measurement for protein quantification. These are ion intensity change mea-
surements, such as peptide peak areas or peak heights in chromatography, and spectral 
counting of identified proteins after MS/MS analysis (Bostanci et al. 2010, 2013, Megger et 
al. 2013).
In study I, concentrations of salivary MMP-8, MPO, TIMP-1 and PMN elastase were cor-
rected for total protein levels. Graph Pad Prism 7 (Graph Pad Software, Inc., La Jolla, CA, 
USA) was utilised for the statistical analyses. Any relationships between LFQ proteom-
ics and IFMA or ELISA data were identified for each analyte using Pearson’s correlation 
test, which is based on log2-fold changes between all different time points. The Friedman 
test was used to investigate how analyte levels varied over the 35 days and differences in 
these levels at different time points were measured with Dunn’s Multiple Comparison Test. 
Mixed-effects multilevel regression analyses were carried out with STATA 14.2 (StataCorp) 
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software in order to gain approximate values for differences in MGI and TQHPI over the 35 
days. P values < 0.05 were considered statistically significant.
In study II, we used (Wilcoxon’s rank sum test) to measure the significant differences and 
associations between two variables; the two variables are aMMP-8 levels in peri-implantitis 
sites measured with the ImplantSafe test and IFMA.
In study III, the correlation between the two variables was measured with the Kruskal–
Wallis test (p < 0.01) and Spearman’s test=1. The Dunn-Bonferroni test and Dunn’s post-
hoc test (p < 0.05) were also utilised. Dunn’s test was used to specify significant means, 
while Dunn’s Multiple Comparison Test specified significant differences between 3 or more 
means. The Dunn-Bonferroni test can be used to study associations between variables and 
also to make comparisons between the participant groups at baseline.
In study IV, G power analysis of MMP-8 biomarker values was used to work out a mini-
mum specimen size, accepting a power of 85% and a p value of < 0.05. The non-paramet-
ric Kruskal-Wallis test, conducted for independent specimens, was carried out to work out 
the statistical dissimilarities among the subject groups. The aMMP-8 test’s precision was 
assessed through receiver operating characteristic curve (ROC) analysis. The Kappa sta-
tistic was utilised to find concurrence among aMMP-8 quantitative determination and the 
result from the test stick. Statistical significance was set at a level of 5%, and this was the 
marker for all analyses that utilised the SPSS 22.0 statistical software program (SPSS for 
Windows; SPSS Inc., Chicago, IL, USA).
In study V, sample size calculations were carried out before the study began in order to 
determine the minimum number of participants. A 0.5-mm mean difference between 
whole-mouth PD values of SDD and placebo groups was considered, and it was assumed 
that the standard deviation in both groups would be 0.5. With a power of 85%, p value = 
5%, normal distribution, and equal variances in the placebo and SDD groups, it was cal-
culated that the minimum sample size required was 14 participants per group. PD was 
chosen as the primary outcome variable, with the secondary outcome variable being GCF 
biomarker levels, and the unit of analysis being a patient. The mean values of whole-mouth 
clinical parameters and the mean values for clinical parameters per patient were averaged. 
The Friedman test was employed to make intragroup comparisons of the clinical parame-
ters as recorded at the baseline and during the 3, 6, 9, and 12 months evaluations. The Bon-
ferroni-corrected Wilcoxon-signed rank test was used to assess the significance of changes, 
while significant differences between the two participant groups were assessed with the 
Mann-Whitney test. Web-based software (R software, version 3.3.1, package: nparLD, R 
Foundation for Statistical Computing, Vienna, Austria) was used to test biochemical vari-
ables with the non-parametric Brunner-Langer model.
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The current study included ten participants who had taken part in the original study 
(Nascimento et al. 2019). They consisted of four males and six females aged between 21-24 
years. Collected samples and data indicated TQHPI and MGI scores (n = 50) in the induc-
tion and resolution phases.
Table 2. Mean and (± SD) for TQHPI and MGI.
 
0.1 ± 0.1, 1.3 ± 0.2 2.2 ± 0.4 2.9 ± 0.4 0.6 ± 0.3
0.0 ± 0.0 0.5 ± 0.1 1.3 ± 0.3 1.9 ± 0.1 0.3 ± 0.4
During phase I, days 0-21, there were continuous increases in both TQHPI and MGI 
scores. However, by the end of R-phase, days +21 - +35, these had reverted to levels similar 
to baseline. Mixed-effects multilevel regression analyses were used to compare all of the 
different time points. Over time, there were notable differences for both TQHPI (p < 0.001) 
and MGI (p < 0.04). Table 2.
In an effort to assess their ability to reflect plaque accumulation and gingival inflammation 
development over time, LFQ proteomics, WB and IFMA were used to measure MMP-8 
salivary level concentration and expression. Readings were taken at baseline (day 0), during 
the plaque accumulation phase (day 0 to day +21), i.e., l-phase, and following the plaque 
removal phase (day +21 to day +35), i.e., R-phase.
It was observed that by using the LFQ proteomics method there were notable differences in 
salivary MMP-8 over time (p < 0.01), which were identified by the Friedman test. In par-
ticular, major MMP-8 differences were observed between day +7 and day +21 (p < 0.05), 
and day +7 and day +35 (p < 0.05). On the other hand, the result we obtained in the Fried-
man test when we used the IFMA method displayed no notable differences over time (p > 
0.05). The expression of different molecular weight forms of MMP-8 was analysed by WB. 
It is evident that during the development and resolution of gingival inflammation (day 0 
to +35), there is latent full-size pro-form MMP-8 expression (proMMP-8: 70-80 [kDa]). 
Discounting their overall MMP-8 concentrations at each point in time, neither sample 
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showed any activated or fragmented MMP-8 (aMMP-8: 50–60 kDa and <45 kDa forms) 
respectively.
ELISA and LFQ proteomics methods were used to measure (n = 50) TIMP-1, MPO, PMN 
elastase. Measurements were taken at baseline (day 0), at day 0 to +21, l-phase, during 
plaque accumulation, and at day +21 to +35, R-phase, following plaque removal. 
Notable differences were observed in the Friedman test, measured by LFQ proteomics, in 
TIMP-1 and PMN elastase salivary levels over time (both p < 0.05). In TIMP-1, in partic-
ular, there was a noticeable difference between day +7 and day +35 (p < 0.05). Whereas, in 
comparison, between day 0 and day +35, there was uncertain significance (p > 0.05). When 
using LFQ proteomics to measure MPO (p > 0.05), no significant variations were observed 
over time.
To establish the association between conventional antibody-based methods and anti-
body-independent discovery proteomics, MMP-8 was used as the gingival inflammation 
model marker. There was a definite association for salivary MMP-8 levels between LFQ 
proteomics and IFMA (p < 0.001) with a Pearson’s correlation coefficient (r of 0.36) result-
ing from time-independent correlation analysis. Further results showed a positive associ-
ation for MPO (r = 0.39, p < 0.0001) and PMN elastase (r = 0.33, p < 0.001), following 
further analyses between ELISA based on TIMP-1, MPO and PMN elastase and LFQ pro-
teomics, while TIMP-1 (r = −0.24, p < 0.05) showed a negative association.
The healthy control subjects were periodontally and systemically healthy dental students 
n=10, and the other n=10 were clinically diagnosed, with X-ray confirmation, to all being 
adult chronic periodontitis patients. A PerioSafe visual test confirmed that all 10 patients 
were aMMP-8 positive. Oralyzer readers quantitated their aMMP-8 lateral-flow test-sticks 
before (all ≥20 ng/ml, visually [+]) and after periodontal treatment, SRP and anti-infec-
tive treatment. The bleeding on probing and pocket depths were reduced with SRP and 
anti-infective treatment. Levels of aMMP-8 in mouth rinse, which were based on visual 
assessments of the test results, changed from positive (+) to negative (−) as a result of SRP. 
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Oralyzer reader quantitation confirmed this by recording readings from ≥20 ng/ml (posi-
tive [+]) to <20 ng/ml (negative [−]). 
In the same study, the experiment showed that in 5 minutes peri-implantitis sites (n = 
29) were detected in the ImplantSafe aMMP-8 PoC/chairside sulcular fluid test sites. This 
allows treatment to be monitored as the test differentiates them from clinically healthy 
peri-implant sites (n = 32). Clinical and X-ray diagnoses were conducted to identify 
peri-implantitis and healthy sites. Elevated aMMP-8 levels were detected in all peri-im-
plantitis sites (29 = 100% ImplantSafe-positive ≥20 ng/ml [124,60 ± 22.50 ng/ml]) . This 
differed from the low aMMP-8 levels (32 sites/<20 ng/ml [18.60 ± 3.46 ng/ml]) present in 
all clinically healthy sites, all of which were ImplantSafe PoC-negative. This difference was 
statistically significant (p < 0.0001 Wilcoxon test). Treatment applied to peri-implantitis 
sites resulted in positive ImplantSafe tests becoming negative. The sensitivity and specificity 
for ImplantSafe tests are 100%, which was clearly demonstrated in the results of this pilot 
case-control study. The quantitated PoC tool, the Oralyzer reader, successfully showed pos-
itive results.
In the same way, the IFMA method was used for quantitative analysis of aMMP-8 from 
PISF, and the quantitated gelatin zymography method was used for the densitometrical 
analysis of all forms of MMP-9 with the same samples of PISF. The IFMA results was cor-
related with ImplanSafe test results, and positively differentiated implant health and dis-
ease. On the other hand, gelatin zymography results indicated that it was not possible to 
differentiate peri-implant health and disease with any form of MMP-9 or total MMP-9.
Table 3. Categorisation of 150 Greek adults according to the new periodontal classification 
system
11 14 39 12 12 47 6
20 1 42 11 2 44 8
The results included 150 Greek adults, which were classified by the new periodontal classi-
fication system. In comparison with healthy patients, aMMP-8 levels in mouth rinse were 
considerably higher in patients with more severe periodontitis stages and grades (Krus-
kal–Wallis test, p < 0.01 and Dunn-Bonferroni test for pairwise post-hoc comparisons, p 
< 0.05). Among the 150 Greek patients, (stage I–III and Grades A–C) were successfully 




The periodontitis stage and grade (Kruskal–Wallis test, p < 0.01) affected both BOP and 
visible plaque index (VPI) values. These two conditions are loosely associated with one 
another (Spearman’s Rho = 0.586, p < 0.001). Also, BOP was more closely associated with 
aMMP-8 levels than plaque levels (Spearman’s Rho = 0.586, p < 0.001; Spearman’s Rho = 
0.269, p < 0.001); respectively.  The risk of increased false positive diagnosis was exhibited 
more in BOP and VPI than compared with the aMMP-8 mouth rinse test. Our group in 
Helsinki University, lead by Professor Timo Sorsa, have modified the new grading system 
based on the mouth rinse test (PerioSafe) and Oralyzer reader according to (Tonetti et al. 
2018)’s periodontitis classification system. Table 4.
5.3.3.1  Assessment of clinical periodontal parameters
In study IV, the two groups with periodontitis significantly differentiated from gingivitis 
and healthy groups (p < 0.05). The gingivitis group and the healthy group had PD and CAL 
scores that were much lower than the stage III and stage IV groups. with statistically signif-
icant differences (p < 0.001). In turn, the gingivitis group’s PD and CAL values were higher 
than the ones in the healthy group (p < 0.05). PI and PBI results were also much greater for 
stage III and stage IV groups, with gingivitis exceeding the healthy group (p < 0.001). The 
stage III and stage IV groups’ location-specific PD and CAL scores were much greater than 
in the other two groups (p < 0.001). While PD and CAL outcomes were equal for the gingi-
vitis and healthy groups (p > 0.05). The scale was similar for PI and PBI, with stage III and 
stage IV being the highest, and gingivitis surpassing the healthy group (p < 0.001).
Positivity levels for the stage III group were 94.4% in regard toaMMP‐8 PoC tests; they 
were 94.7% for the stage IV group, 81% for the gingivitis group and 18.2% for the healthy 
group. The aMMP-8 activity of the selected cut-off point resulted in sensitivity of 83.9% 
and specificity of 79.2%. The ROC curve demonstrates aMMP-8’s diagnostic outcome in 
relation to periodontitis. aMMP-8 activity displayed accuracy within good ranges (AUC = 
0.87, 95% CI 0.799-0.958).
 
In study III, the format of this study allowed for the comparison of salivary aMMP-8 IFMA 
measurements with aMMP-8 PoC/chairside mouth rinse tests. The same antibody was used 
in both methods. In a sample of Greek adults, it was found that the mouth rinse aMMP-8 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































patients showed no positive aMMP-8 mouth rinse test results. The sensitivity of the test was 
comparable with an increasing number of periodontal pockets. Same results were observed 
in study IV, when we compare GCF with salivary MMP-8 using the IFMA method. The 
stage IV group’s GCF aMMP-8 IFMA levels were greater than those for stage III, gingivitis 
and healthy groups (p = 0.01, p = 0.001, p = 0.00, respectively). The healthy group in turn 
had much lower levels (p < 0.05) than stage III and gingivitis groups, and the aMMP-8 
IFMA levels were similar for the stage III and gingivitis groups (p > 0.05). While in salivary 
samples, stage III, stage IV and gingivitis groups had much greater levels of saliva aMMP-8 
than the healthy cohort (p = 0.00), but there was little variation between the first three 
groups (p > 0.05).
Both the demographics of patients, relating to gender, age and smoking habits, were sim-
ilar in the SDD (n = 15) and placebo (n = 15) groups (p > 0.05). The study groups showed 
almost the same baseline clinical periodontal parameters (p > 0.05). There were noticeable 
improvements in the periodontal conditions of both the SDD and placebo groups between 
the baseline and the re-examinations at 3, 6, 9 and 12 months (p < 0.0125). 
During the study period, there was a marked decrease in the whole-mouth CAL of the SDD 
group (p < 0.0125), in comparison with the placebo group, where there was a noticeable 
improvement in whole-mouth CAL scores at 3 months (p < 0.0125). At other time points, 
there were no significant changes (p > 0.0125) in the placebo group.
At the 6, 9 and 12-month follow-up examinations, there was more PD reduction in the SDD 
group than in the placebo group (p = 0.04, p = 0.02, and p = 0.04, respectively). However, 
at 3 months, both had shown similar PD reductions (p > 0.05). The SDD group showed a 
marked improvement over the placebo group in CAL, which was most pronounced at 6 
and 9 months (p = 0.04, p = 0.04, respectively).
At other time points, both groups displayed similar whole-mouth CAL scores (p > 0.05). At 
3, 6 and 9 months, the SDD group displayed significantly improved GI scores in compari-
son with the placebo group (p = 0.01, p = 0.01, and p = 0.01, respectively). Throughout the 
entire study period, both groups showed a significant equal reduction in their PI scores (p 
> 0.05). 
Generally, at baseline, the SDD (n = 15) and placebo (n = 15) groups showed similar results 
between the mean values of the studied clinical parameters and GCF of the study sites (p > 
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0.05). At 3 months, there was a noticeable improvement, and this was continued through-
out the 12-month study period in comparison to baseline (p < 0.0125). No noticeable dif-
ference was noted between the groups at any of the time points (p > 0.05).
MMP-8
There was an equivalent amount of GCF MMP-8 at baseline for both groups (p > 0.05). At 
the 12-month point, there was a marked decrease in the total amount of GCF MMP-8 in 
comparison to baseline (p < 0.05). However, at the 6-month mark, it was observed that the 
SDD group showed a greater decrease in comparison to the placebo group, yet the differ-
ence was marginal. The total amount of GCF MMP-8 remained stable during both groups’ 
periods for the remainder of the study.
MMP-9
At baseline (p > 0.05), the GCF MMP-9 total amounts were alike both for the SDD and pla-
cebo groups. Thereafter, compared to baseline, there was a marked decrease in both groups 
at the 12-month point (p < 0.05). However, it was observed that, in comparison to the pla-
cebo group, the SDD group displayed a greater decrease in the third month. Thereafter, 
both groups showed a similar decrease pattern. Thereafter, even though levels were still 
considerably lower than the baseline levels, no more decrease was noted in either group. 
MPO
There was a marked MPO decrease in both groups, and at all times, compared to baseline 
(p < 0.05). The total GCF amount recorded a decrease in the third month in comparison 
with the placebo group, in a similar manner to the MMP-9 pattern. Following similarities 
in the sixth month, the placebo group showed an increased level throughout the remainder 
of the study period. In the SDD group, there was a continued decrease in GCF MPO levels 
over the period of 12 months. 
OPG
At baseline, both groups had similar total GCF OPG amounts (p > 0.05). This decreased 
considerably in both groups, when measured at all time points, in comparison to baseline 
(p < 0.05). From the third to the twelfth month, there was an increased change in the pla-
cebo group, whereas GCF OPG levels continued to decrease in the SDD group over the 
period of 12 months.
In a major part of the study population, both GCF TRAP-5 and MMP-13 levels remained 
below the detection level. Half of the population, 15 of the 30 participants, was observed 
to having MMP-13, and only 5 of the 30 CP patients (17%) in the baseline samples were 
detected of having TRAP-5.   
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This thesis has identified and presented commercially available lateral-flow immunotests 
based on aMMP-8 oral fluid -specific PoC, chairside, namely PerioSafe and ImplantSafe, 
together with the digital Oralyzer reader, for the diagnosis of periodontal and peri-im-
plant diseases. Various oral fluids, such as saliva, GCF, PISF and mouth rinse were studied. 
The tests differentiated periodontal and peri-implant health and diseases in an excellent 
manner. In addition to this, the PerioSafe test (mouth rinse test) can be incorporated as the 
staging and grading biomarker in the new classification system of periodontitis. LFQ can 
quantify enzyme levels in saliva, significant but weak correlations between IFMA or ELISA 
and LFQ. The use of SDD as an adjunctive for three months to non-surgical periodon-
tal therapy compared to non-surgical periodontal therapy alone in periodontitis patients’ 
results in the further improvement of clinical periodontal parameters and GCF biomarkers 
of periodontal tissue breakdown over a 12-month period. 
Periodontitis is considered to be the sixth most prevalent chronic inflammatory disease 
worldwide (Kassebaum et al. 2014). According to the current interpretation of etiopatho-
genesis, a prime issue in the incipience and development of periodontal diseases is the host 
immune response (Nascimento et al. 2017). Dysbiotic plaque accumulation generates a 
host immune-inflammatory reaction, whereby neutrophils are attracted to the infected site 
by chemokines and pro-inflammatory cytokines (Scott et al. 2012). Thereafter, neutrophils 
and other cells, including plasma and gingival sulcular epithelial cells and fibroblasts, result 
in the release of proMMP-8, a latent form of MMP-8 (Kinney et al. 2007). The facilitation of 
leukocyte migration, in particular neutrophil granulocytes, towards the periodontal sulcus 
by cleaving collagens and other extracellular matrix components, is the prime biological 
function of MMP-8 in the periodontium (Kinney et al. 2007). The destruction of inflam-
mation-related tissues in periodontitis, and the presence of other inflammatory diseases, 
results from the copious and non-controlled expression, release and activation of MMP-8 
together with other MMPs (Nagase et al. 2003). MPO is the main cause of oxidative burst 
and host-derived proteases leading to MMP-8 activation. MMP-8 can also be activated by 
bacteria derived from proteases, such as T denticola (dentilisin) or P gingivalis (gingipains) 
(Amulic et al. 2012, Gursay et al. 2018).  
MMP-8 is a major subject of MMP periodontal research. There is the possibility of clinical 
mismanagement, albeit inadvertent, as a consequence of evidence-based knowledge pau-
city concerning disease progression. Diagnostic procedures are intended for the purpose 
of gaining pertinent information on the current periodontal disease type and level of seri-
ousness. Enabling the verification of disease monitoring and treatment planning is required 
during periodontal management (Slots 2013). Advances in diagnostic research and tech-
Discussion
56
nological development indicate that there is a likelihood of new methods being available 
for identifying individual periodontal risks, and the use of objective biomarkers to quantify 
risk (Ozmeric 2004, Taba et al. 2005).
Biomarker’s research aims to identify markers for the present and future state of periodon-
tal disease (Ozmeric 2004). Over the past 20 years, a range of immunological and micro-
biological methodologies have been reported as diagnostic tests. Nevertheless, it is a major 
requirement to ensure that the efficiency standards are set at a high level to allow peri-
odontal diseases to use adequate, evolutionary biomarkers. Periodontitis is an infectious 
and inflammatory chronic disease with three stages of infection, inflammation and tissue 
destruction. Consequently, biomarker research aims to develop an effective biomarker that 
can identify at least one of these stages (Curtis et al. 1989, Kinane 2000).
Research has shown that increased levels of active MMP-8 in oral fluid, excluding its latent 
form, are associated with progressive clinical periodontal and peri-implant disease activity 
(Sorsa et al. 2006, Al-Majid et al. 2018, Leppilahti et al. 2018). Oral salivary collagenase in 
periodontal or peri-implant patients is found in active or activated MMP-8 form in com-
bination with activation fragments, whereas, in an uninfected mouth, it is in latent form 
(Uitto et al. 1990, Sexton et al. 2011). Current and future, or developing, progressive peri-
odontal and peri-implant disease activity can be indiscernible and subclinical. It is evident 
from active MMP-8 in oral fluids. MMP-8 is associated with, and precedes and predicts 
disease, such as CAL, active periodontal and peri-implant degeneration. A close link has 
been established between progressing severity of periodontal and peri-implant diseases and 
aMMP-8. The pronounced reduction of aMMP-8 in oral fluids results in successful peri-
odontal and peri-implant treatment (Killi et al. 2002, Pozo et al. 2005, Sorsa et al. 2016).
Analysis of the diagnostic accuracy, namely the sensitivity and specificity of molecular bio-
markers in GCF, was conducted in a recent systematic review and meta-analysis to estab-
lish the detection of periodontitis in systematically healthy subjects (Bujanda et al. 2019). 
MMP-8 was found to be the best performance marker, displaying a sensitivity and specific-
ity median of 77% and 92%, respectively. This result was taken from a total of 36 potential 
biomarkers reported in 19 different research papers.  
According to Giannobile et al. (2009), the early identification of active disease status, and 
the ability to monitor the response to periodontal therapy, requires the development of 




The tests of a recently developed PoC system for the diagnosis of periodontitis and 
Peri- implantitis have resulted in promising diagnostic accuracy. The aMMP-8 test uses oral 
fluid. Test results verifying the diagnostic accuracy of the tests have been published for gen-
eral use. The test is easy-to-use, and the system is similar to that of a pregnancy test kit 
(Sorsa et al. 2016, Heikkinen et al. 2016, 2017, Al-Majid et al. 2018).
The aMMP-8 tests and digital readers are simple to use, inexpensive, have high sensitivity 
and specificity and if used in a clinical setting, they can give rapid results with accuracies of 
90% and 75-85%. The concept is innovative in that it uses a diagnostic approach to measure 
the active isoform of the enzyme and does not aim to measure the total MMP-8 concen-
tration. The aMMP-8 test focuses on identifying the destructive inflammation process by 
using a monoclonal antibody developed to target aMMP-8 (Sorsa et al. 2006, 2016, Al-Ma-
jid et al. 2018).
Comprehensive research has been conducted into whether oral fluids could be used to 
locate biomarkers that were capable of diagnosing periodontitis. A biomarker that has 
attracted a lot of research attention in this field is MMP-8. The early identification of 
pre-periodontitis and pre-peri-implantitis can signify the prevention of future periodon-
tal and peri-implantitis destruction (Axelsson et al. 2004, Thierbach et al. 2016, Ziebolz et 
al. 2017). Timely identification of otherwise invisible destruction, or the inception of peri-
odontal or peri-implant collagenolysis, will allow appropriate treatment, such as secondary 
prevention, together with supportive periodontal or peri-implant measures to be admin-
istered (Ebersole et al. 2015, Ramseier et al. 2016, Rathnayake et al. 2017). Several studies 
(Lee et al. 1995, Romanelli et al. 1999, Kiili et al. 2002, Sorsa et al. 2006) have observed and 
recorded that elevated levels of aMMP-8, excluding latent and total MMP-8, constitute a 
forerunner in periodontal destruction. These levels can distinguish between gingivitis and 
periodontitis, and abnormally high levels of aMMP-8 illustrate that the active period of 
periodontal disease has begun. It can provide patients of any age or ethnic background 
effective treatment (Nwhator et al. 2014, Sorsa et al. 2016, Johnson et al. 2016, Al-Majid et 
al. 2018, Zhang et al. 2018, Raivisto et al. 2019). The condition can be monitored for both 
periodontitis and peri-implantitis.
The methodology used in study II, PerioSafe and ImplantSafe, together with a digital Ora-
lyzer reader for quantitation were used to correlate periodontal and peri-implant param-
eters. Pre- and post-treatment and the baseline test results showed a marked differential 
between healthy samples and diseases. Sensitivity and specificity were 100% for all sam-
ples in terms of positive PerioSafe and ImplantSafe tests showing up as negative. IFMA was 
used to measure the aMMP-8 levels in PISF; zymography methods were used to measure 
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MMP-9. All peri-implantitis sites displayed elevated aMMP-8 levels detected by IFMA. 
However, gelatinolytic activation of MMP-9 could not differentiate peri-implant health or 
disease. So, the results are in line with previously published literature.
An aMMP-8 test in an earlier study accurately separated adolescent gingivitis or ini-
tial periodontitis patients from participants in good health on the basis of earlier radio-
graphic examinations (Heikkinen et al. 2016, 2017). Additionally, there was an associ-
ation between positive test outcomes and participants having a genetic predisposition to 
periodontitis. Heikkinen et al. (2017) discovered that MMP-3 genetic polymorphism and 
vitamin D receptors associated with early stages of periodontitis in Finnish adolescents. 
Perio Safe mouth rinse tests are able to be adapted for detecting early stages of periodontitis 
or pre-periodontitis in adolescents with predisposed genes. Researchers have revealed that 
increased aMMP-8 levels have been observed among type 1 and type 2 diabetes patients 
(Cervino et al. 2019, Fiorillo et al. 2019). Similarly, recent research has indicated the suit-
ability of the PoC aMMP-8 test for discerning pre-diabetes and diabetes in dental manage-
ment (Grigoriadis et al. 2019).
The aMMP-8 PoC test has some limitations, including patients under the age of 15, those 
having active orthodontic phase treatment, pericoronitis, or a mouth ulcer. These condi-
tions can result in the aMMP-8 PoC test not successfully identifying periodontal diseases in 
patients and thereby generating incorrect results. Rautava et al. (2020) conducted a recent 
study in which it was discovered that the oral rinse aMMP-8 test to identify periodonti-
tis appears to work less well for Crohn’s disease (CD) patients than for generally healthy 
people. The aMMP-8 test’s sensitivity and specificity assessments for discerning periodonti-
tis were much less effective for CD patients (60.0% and 75.0%) than fundamentally healthy 
people (90.9% and 80.0%).
The new periodontal classification system contains grading parameters that could ascertain 
the prospects of periodontitis amplifying. These parameters were not reliable enough to 
confirm with any certainty when the periodontitis active period would happen, even when 
taking into account risk factors, such as smoking and diabetes (Leite et al. 2018, Nasci-
mento et al. 2018). This leads to the need stronger biomarkers to be introduced that might 
permit dentists to determine if the periodontitis is in its active period (continuing peri-
odontal breakdown). Dentists would then be able to track the disease’s path and choose 
forms of treatments that would be most effective (Tonetti et al. 2018). 
Disease progression monitoring requires radiographic and visual observations together 
with a range of measurements, such as PD and BOP, together with attachment loss. It is 
a technically complex evaluation requiring a high level of specialist skills. The most evi-
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dent negative predictor of periodontal disease activity is BOP. The sensitivity value of the 
test is low, and no evidence of bleeding indicates a lack of periodontal tissue destruction. 
The diagnosis of current disease activity is not indicated by diagnostic tests, such as CAL 
loss and PD (Buduneli and Kinane, 2011), as they are only indicators of previous tissue 
destruction.
Our recent study III has enabled us to demonstrate aMMP-8 levels, BOP and VPI in a 
sample of 150 Greek participants who have been categorised according to the new classi-
fication system. Confirmation has been achieved for the usefulness of aMMP-8 as a stage 
and grade biomarker in the 2018 system of classification. The outcomes have demonstrated 
that there is a positive connection between the acuteness of periodontal disease and its 
grade, which suggests to what extent the disease may amplify. The outcome concurs with 
prior research that has indicated that aMMP-8 is very effective at predicting periodontal 
breakdown (the positive predictive values are between 81.8%–94.7%) Similarly, there was 
also an association between degrees of BOP and VPI levels and the stage and grade of peri-
odontitis, although there was only a small degree of correlation between the parameters 
of BOP and VPI. Prior research has displayed that BOP only weakly forecasts future peri-
odontal breakdown (the positive predictive value for repeated BOP occurrence was ≤ 30%). 
However, the sustained non-appearance of BOP is correlated much more with periodontal 
stability, while the joint cut-off points of BOP and VPI are capable of generating more false 
positives results (Buduneli and Kinane, 2011). BOP and VPI levels had a wide range of 
occurrence in healthy patients as opposed to patients with disease (Stages I–III and Grades 
A–C). In terms of periodontitis patients, this applies as much to Grade A patients’ BOP and 
VPI levels as it does to Grade B patients. In addition, the overlap in degrees of BOP and 
VPI between diverse classifications increases the possibility of false positives being diag-
nosed. On the contrary, aMMP-8 tests did not show similar overlapping and there appeared 
to be a significantly reduced chance of false positives than from either BOP or VPI. Overall, 
aMMP-8 test proved to be the preferred indicator for differentiating between periodontal 
health and disease.
Similarly, in our study IV, we have explored the possibility of GCF aMMP-8 levels being 
linked with the various periodontal disease stages, as well as general periodontal health, by 
utilising an aMMP-8 PoC dip-stick test and IFMA. The most recent categorisation of peri-
odontitis was adopted to classify the 80 Turkish participants of this research in the various 
phases of gingivitis, Stage III, Stage IV and health. Our goal was to appoint aMMP-8 as 
the designated biomarker for this new periodontitis classification system (Papapanou et al. 
2017, Tonetti, Greenwell & Kornman 2018).
The key discovery of the research has been the recognition of an association between 
increased GCF aMMP-8 levels and a greater intensity of periodontal disease. Crucially, if 
aMMP-8 is not present, but latent, pro- or total MMP-8 is, this indicates a healthy indi-
vidual. The degree of the disease was linked to higher values of PD, CAL, and PI. The 
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diagnostic precision of aMMP-8 PoC dip-stick tests in GCF samples was indeed of a high 
order (87%) (AUC = 0.87, 95% CI 0.799-0.958), allowing for the differentiation of phases 
of periodontal disease and health provided by the aMMP-8 biomarker. Such a positive link 
among aMMP-8 degrees and periodontal disease phases shows how useful this biomarker 
is in accurately assessing periodontal disease in accordance with the new classification of 
periodontitis. In our study IV, our results showed that higher GCF aMMP-8 levels in the 
stage IV group, as well as in stage III and gingivitis groups in comparison with the healthy 
cohort, supports the positive role of MMP‐8 in periodontal and peri-implant pathogene-
sis as well as its biomarker role in screening, diagnosis and prevention. Positive aMMP-8 
test outcomes were much more apparent in periodontitis (nearly 95%) and gingivitis (81%) 
groups, compared to the healthy cohort (18.02%). The indication from this is that chairside 
and quantitative trials could screen, discover and distinguish sites that were healthy or had 
gingivitis from periodontitis locations, and therefore indicate the risk of gingivitis at an 
early stage. It should be stressed that aMMP-8, excluding total or latent aMMP-8, is known 
to be present before serious periodontal degradation and elevated levels of aMMP-8 in oral 
fluids. Therefore, it can also provide a warning of periodontal tissue destruction. In study 
I, we showed that during the induction and resolution phase of gingival inflammation, it 
was latent MMP-8 that was present, not active MMP-8. Previous research has reported that 
there are links between progressive periodontitis and active aMMP-8 in oral fluids, while in 
gingivitis and healthy fluid, latent enzymes were most prolific (Sorsa et al 2017, Al-Majid et 
al. 2018).
(Raisanen et al. 2020)’s prior research demonstrated mouth rinse aMMP-8 measurements 
to be more effective and have greater accuracy in discerning adolescents’ predisposition to 
periodontal health and disease as opposed to aMMP-8 saliva tests. This process was car-
ried out several times and further progressed in our study III and IV when we compared 
the aMMP-8 mouth rinse and GCF test results to aMMP-8 IFMA saliva assessments using 
the same antibody in each method. Mouth rinse aMMP-8 test assessments showed more 
accurate results and provided no false positives. On the contrary, when IFMA assessments 
of aMMP-8 saliva levels were carried out, they provided a less clear categorisation of peri-
odontal health and disease. We discerned aMMP-8 mouth rinse test measurements to 
appear to be the best way of assessing active periodontal breakdown and the possibility of 
future periodontal disease. Our recommendation is that aMMP-8, together with the mouth 
rinse test PerioSafe with the Oralyzer reader, should form an element of the new periodon-
tal disease classification system, so as to raise the precision of periodontal disease diagnosis 
and its progression. 
6.4  
In the period between the late 1950s and early 1960s, the idea began to evolve that there 
might be a link between the proteins found in oral fluids and the presence and activity 
Discussion
61
of periodontal disease. Although proteomics have facilitated the identification and valida-
tion of a number of potential biomarkers, to date none have been discovered that can be 
applied to the diagnosis of periodontal disease (Bostanci et al. 2017, 2018). LC-MS-based 
proteomics and conventional antibody-based methods ELISA and IFMA were assessed 
in our present study I to find out if they would be able to provide a quantitative measure 
of salivary biomarkers of periodontal disease. The participants of the study had induced 
gingival inflammation development. The model biomarkers that were utilised included 
MMP-8, TIMP-1, MPO, and PMN elastase. Antibody-based immunoassays were used 
as the main technique for quantifying proteins that target a specific protein. In the cur-
rent study, the LFQ approach successfully identified and quantified the biomarkers, which 
were being tested for the presence of periodontal disease. The analysis revealed a signif-
icant, albeit weak correlation, between the IFMA immunoassay or commercial ELISAs 
and the LFQ approach. In addition, there was positive and significant correlation between 
MMP-8, MPO, and PMN elastase, and LFQ proteomics and IFMA or ELISA. On the other 
hand, there was a negative relationship for TIMP-1 (LFQ versus ELISA). One explanation 
for the difference may be that PMN elastase and MPO share a neutrophil origin, whereas 
TIMP-1 has a fibroblastic/mesenchymal cell lineage origin, i.e. a non- neutrophil lineage. 
In the same study, WB analysis was also used to assess the molecular forms of MMP-8. 
This research is the first to demonstrate that MMP-8 activation does not occur during the 
induction and resolution phases of experimentally induced gingival inflammation; instead, 
it was found to be present in its latent, proMMP-8 form. This finding could be important 
for identifying the mechanisms and processes involved in gingivitis developing into peri-
odontitis. One limitation of the study could be the fact that the sample size only consisted 
of 10 participants. However, the study results still show a significant correlation between 
immunoassays and LFQ proteomics in terms of the assessed biomarkers. 
One potential method for managing periodontal disease is through the modulation of the 
host response. The anti-microbial effect of doxycycline is based on its ability to inhibit the 
gingival tissues and GCF collagenase activity of chronic periodontitis. Therefore, it decreases 
connective tissue destruction and the resorption of alveolar bone (Golub et al. 1998, Caton 
et al. 2000). The use of SDD has been assessed in several studies, which have analysed SDD 
therapy’s adjunctive effect and ability to modulate host activity. Typically, SDD therapy is 
prescribed for a period of 14 days to 24 months (Preshaw et al. 2004, Golub and Lee 2020). 
In our present study V we assessed adjunctive SDD for 3 months to determine its effective-
ness on clinical parameters and GCF MMP-8, MMP-9, MMP-13, MPO, TRAP-5, and OPG 
levels in patients with chronic periodontitis. The study was a double-blinded, placebo-con-
trolled, parallel-arm study. The results were evaluated in chronic periodontitis patients over 
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a 12-month period and compared with those obtained for patients subject to only non-sur-
gical periodontal therapy. We found both treatments resulted in significant improvements 
in the management of chronic periodontitis; the adjunctive SDD was clinically the most 
beneficial. 
In regard to reducing periodontal disease and retaining clinical attachment, the findings 
of the study, in which adjunctive SDD was found to be clinically more beneficial than SRP 
therapy alone, add to and confirm the findings of previous researchers (Walker et al. 2000, 
Golub et al. 2001). The current study prescribed SDD in addition to SRP over a period of 
three months, which is shorter than that employed in past studies (Thomas et al. 1998, 
Golub et al. 2001). In order to minimise confounding factors, both groups in our study had 
similar levels of MMP-8, MMP-9, GCF and MPO levels at baseline. When adjunctive SDD 
or SRP therapy had been administered, the overall GCF MMP-8, MMP-9, and MPO levels 
reduced noticeably. When undergoing active periodontal treatment, both groups of partic-
ipants experienced reduced levels of GCF biomarkers. This suggests that being instructed 
on oral hygiene and receiving SRP therapy, i.e. non-surgical periodontal therapy, reduces 
the presence of oral bacteria. However, there was a temporary decrease in these biomarkers 
when SRP therapy was administered alone, while SDD achieved stable biomarker reduc-
tion over the period of 12 months. Thus, it appears that mechanical treatment was only 
able to achieve a temporary reduction in biomarker levels, whereas SDD stabilised them 
for 12 months. Nevertheless, the difference was statistically insignificant. In a short-term 
study carried out over two weeks, collagenase activity was seen to reduce by 60–80% with 
SDD. This indicated that TCs were able to reduce the severity of inflammation, which in 
turn prevented periodontal tissue breakdown (Golub et al. 1990, 1998). The findings of this 
study, our previous studies and research carried out by others, confirm that the expres-
sion of host collagenases/MMPs can be downregulated or reduced with adjunctive SDD 
therapy by means of a mechanism that is not related to the drug’s antimicrobial properties 
(Preshaw et al. 2004, Golub et al. 1990, 1998). This points to a potential benefit of MMP’s 
inhibition of doxycycline; it could constitute a safe form of therapy that does not affect 
the normal remodelling of connective tissue but is able to effectively reduce excessive col-
lagenase levels. Our study was the first one to evaluate SDD’s adjunctive effect for GCF 
bone turnover biomarkers, TRAP-5 and OPG. GCF TRAP-5 levels of the chronic peri-
odontitis patients in this study were measured, and approximately 17% of the participants 
were found to have TRAP-5. In both groups of this study, the total amount of GCF OPG 
reduced significantly in comparison to the baseline, although it increased for the placebo 
group from three to twelve months. The levels in the SDD group reduced continuously 
over the 12 months. With SDD therapy, past research has found that host modulate therapy 
(HMT) treatment (non-antibiotic-dose doxycycline MMP-inhibitor) reduced the severity 
of chronic periodontitis, the circulating levels of CRP, TNF-α and IL-6, which are biomark-
ers of systemic inflammation, and MMP-8 and MMP-9. The data from our study indicates 
that treating patients for three months will have long-lasting beneficial effects (Salvi et al. 
2005, Golub et al. 2020).
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A limitation of the present case series study was the small sample sizes: study I, n = 50, 
study II, n = 80, study IV, n = 80 and study V, n= 30. Larger sample sizes would allow the 
findings to be more reliable. This was the first-time studies such as performed in writing 
with ImplanSafe and Oralyzer, so it was realistic to keep the study groups small.
A strength of our study was the large sample size in study III, n=150. Furthermore, the par-
ticipants were examined by a highly trained periodontist. During the last decade, MMP-8 
research has increased significantly. Professor Timo Sorsa invented the aMMP-8 test, which 
was improved and updated during the last several years and are accepted by US FDA now-
adays. PerioSafe and ImplantSafe with the Oralyzer reader were the last updated tests for 
qualitatively and quantitatively measuring aMMP-8 levels in oral fluids. In my studies, 
we approved and confirmed the reliability and efficacy of these tests. In the same way, we 
demonstrated the performance of aMMP-8 as a biomarker test in grading and staging of 
periodontal diseases according to the new periodontal classification system. We also made 
comparisons with clinical periodontal examination, such as BOP and PI. 
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1.  There was a correlation between increased aMMP-8 levels in oral fluids and radio-
graphic and clinical parameters. The use of PerioSafe and ImplantSafe with the Ora-
lyzer reader to analyse oral fluids proved to be highly capable of differentiating site- 
and patient-specifically between periodontal and peri-implant health and diseases. 
Therefore, they can be strongly considered to be valid diagnostic, prognostic, and pre-
ventive PoC chairside technologies for periodontal and peri-implant diseases.
2.  The ImplantSafe PoC chairside test and IFMA were able to measure aMMP-8 levels 
and effectively differentiate between diseased and healthy samples and sites, whereas 
zymography method targeting could not differentiate all or selective forms and total 
MMP-9.
3.  Following the above mentioned, we can confirm that the aMMP-8 mouth rinse test 
can be employed as an adjunctive tool for diagnosis in order to identify or help to 
prevent periodontitis. It enables the application of required biomarkers in the clas-
sification of disease by stage and grade. Additionally, active ongoing periodontal 
breakdown can be assessed quantitatively at the point-of-care in a very short time, 
approximately five minutes. In general, our results indicate that it will be beneficial to 
incorporate aMMP-8 as the biomarker needed and wanted in the new (Tonetti et al. 
2018) periodontitis classification system. This test may be a worthwhile adjunctive tool 
for diagnosis and prevention, assisting traditional approaches in the identification of 
periodontal disease. 
 A further reason to encourage its use is that it does not lead to an increase in false pos-
itive results, unlike BOP and PI. It is also anti-invasive and never causes bacteraemia.
4.  The results of our studies III and IV revealed that the aMMP-8 measurements from 
mouth rinse and GCF are more accurate for the identification of periodontal diseases 
and health than those taken from saliva. When saliva was used as a matrix for peri-
odontitis biomarkers, the results were inexact and erroneous.
5.  LFQ proteomics have been shown to be able to accurately quantify and identify the 
biomarkers in saliva. Furthermore, this method was able to measure these marker 
levels during the accumulation of plaque, thus showing changes caused by gingival 
inflammation. The fact that the correlations between the immunoassays tested here 
and LFQ were weak leads to a call for strategies that employ “anti-peptide” antibody 
development, with the latest targeted proteomic approaches based on LFQ (Bostanci 




6.  Our results suggest that providing SDD adjunctive therapy for patients with chronic 
periodontitis for three months together with non-surgical periodontal therapy, in com-
parison with non-surgical periodontal therapy alone, leads to an improvement in clin-
ical periodontal parameters and GCF markers of periodontitis over a period of twelve 
months. It is likely that adjunctive SDD therapy’s benefits are linked to decreased levels 
of two MMPs associated with periodontitis, i.e., MMP-8 and MMP-9, and their poten-
tial oxidative activator MPO.
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